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Appropriate polypharmacy – prescribing for an individual for complex conditions or for 
multiple conditions in circumstances where medicines use has been optimised and where 
the medicines are prescribed according to best evidence. 
  
Adverse Drug Reaction (ADR) – an unwanted or harmful reaction experienced following 
the administration of a drug or combination of drugs under normal conditions of use and is 
suspected to be related to the drug 
 
Cultural competency – the ability to participate ethically and effectively in personal and 
professional intercultural settings. It requires being aware of one’s own cultural values and 
world view and their implications for making respectful, reflective and reasoned choices, 
including the capacity to imagine and collaborate across cultural boundaries 
 
Clinical indication – the condition, symptom or reason that a medicine is being 
prescribed to manage or treat for this patient.   
 
Dependence Forming Medicines (DFM) – are, primarily, opioids, z drugs, 
benzodiazepines, Gabapentin and Pregabalin. Dependence in this case is defined as the 
need to continue taking a medicine to maintain a state of normality and avoid symptoms of 
withdrawal. 
 
Deprescribing – a collaborative process, with the patient and/or their carer, to ensure the 
safe and effective withdrawal of medicines that are no longer appropriate, beneficial or 
wanted, guided by a person-centred approach and shared decision-making. 
 
Inappropriate or problematic polypharmacy – the prescribing of multiple medications 
inappropriately or where the intended benefits of the medications prescribed are not 
realised. 
 
Medicines reconciliation – the process of identifying anomalies in what the prescribing 
records says a patient should be taking, compared to the medicines the patient is in fact 
receiving and taking. 
 
Medicines optimisation – a person-centred approach to safe and effective medicines 
use, to ensure people obtain the best possible outcomes from their medicines. 
 
Overprescribing – the use of a medicine where there is a better non-medicine alternative, 
or the use is inappropriate for that patients’ circumstances and wishes. 
 
Personalised care – care based on ‘what matters’ to people and their individual strengths 
and needs. A change to the one-size -fits-all health and care system. The Comprehensive 
Model of Personalised Care has six evidence-based components: sharing decision-
making, personalised care and support planning; enabling choice; social prescribing; 
supported self-management; and personal health budgets. 
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Polypharmacy – the concurrent use of multiple medicines for one person. There is 
currently no consensus on a definition for polypharmacy. The World Health Organisation 
defines polypharmacy as four or more medicines, academia tends to use five or more, 
NHS Scotland uses 10 whilst practice data tends to be based on the NHS Business 
Services Authority polypharmacy definitions that start at eight unique medicines. In this 
report we have calculated the prevalence of polypharmacy at both 5+ and 8+. 
 
Primary Care Network (PCN) – a group of general practices joined as a network, typically 
covering 30,000-50,000 patients. The networks will provide the structure and funding for 
services to be developed locally, in response to the needs of the patients they serve. 
 
Rethinking Medicine – a collaborative initiative that focuses on quality of life and well-
being rather than pathology, clinical states or markers of disease. 
 
Shared Decision Making (SDM) – a collaborative process between a clinician and a 
patient, where the clinician supports the patient to reach a decision about their treatment 
that is right for them. It brings together the clinician’s expertise of treatment options, 
evidence, risks and benefits and the patients’ circumstances, goals values and beliefs. 
 
Social prescribing – a way for local agencies to refer people to a link worker. Link 
workers give people time, focusing on ‘what matters to me’ and taking a holistic approach 
to people’s health and wellbeing. They connect people to community groups and statutory 
services for practical and emotional support. 
 
Structured Medication Review (SMR) – a comprehensive and clinical review of a 
patient’s medicines and detailed aspects of their health. Delivered by facilitating shared 
decision-making conversations with patients aimed at ensuring that their medication is 
working well for them. 
 
Transfer of care – when a person moves between care settings or care is handed over 
from one medical professional to another. 
 
Unique medicines – one or more medicines prescribed as the same chemical substance 





For the NHS, as for the communities it serves, COVID-19 continues to be a hugely 
challenging experience. Yet among the tragedy and heartbreak of this year there has been 
a real spirit of togetherness and millions of people have stepped up to support those who 
are in need. 
 
This report seeks to build on that spirit. It recognises that generally the NHS has a strong 
track record of evidence based prescribing and rational use of medicines. The 
achievements of the NHS in partnership with others to address the problem of 
overprescribing so far, in terms of optimising the use of medicines, developing better 
systems and listening to the needs and preferences of patients. And it points to where we 
need to go in future. 
 
COVID-19 has made the case for change even stronger. As we look to learn from what 
has happened, and do things differently, we need to build in improvements so we reduce 
overprescribing once and for all. In January 2019 the NHS Long Term Plan set out the key 
themes for the NHS: preventing illness, tackling health inequalities, improving care quality, 
providing digitally-enabled care and backing our workforce – all of which are picked up in 
our recommendations. The Long Term Plan is also putting new resources into the NHS 
and it is vital that we get the most from these investments.  
 
Overprescribing is a complex issue, involving systems and culture as well as individuals, 
and tackling it needs a system-wide response, with clinicians and patients both receiving 
more support to ensure the NHS is getting prescribing right. During the review, we heard 
from hundreds of patients, clinicians and experts who helped us to identify a range of ways 
in which we can improve prescribing systems and culture and these form our proposed 
strategy for reducing overprescribing. We also have to recognise how much more we need 
to know: our recommendations on research are fundamental to our ability to continue to 
reduce overprescribing. 
 
If we invest in tackling overprescribing as this report recommends, then we estimate the 
NHS will be able to reduce the volume of items dispensed in primary care in England. With 
well over a billion items dispensed each year, there is a huge prize to be gained in 
improving the health of millions of people – comparable to a new ‘blockbuster’ medicine – 
if we can only get this right.  
 
Medicines do people a lot of good and this report is absolutely not about taking treatment 
or services away from people where they are effective. But medicines can also cause 
harm and can be wasted. Building on important initiatives now underway, including the 
rapid expansion of clinical pharmacists alongside GPs, and the scaling up of social 
prescribing. This report shows how the NHS can make the most of a once in a generation 
opportunity to reset prescribing in a new, patient-centred way.  
 
Dr Keith Ridge CBE 
Chief Pharmaceutical Officer for England 
  




This review was set up to develop recommendations to reduce overprescribing, which is 
where people are given medicines they don’t need or want, or which may do them harm. 
(See 'This review' section.) 
 
The review has found that overprescribing is a serious problem in health systems 
internationally that has grown dramatically over the last 25 years. (See 'The causes of 
overprescribing' section.) It has two main causes:  
 
• systemic: key factors are single-condition clinical guidelines, a lack of alternatives 
to prescribing a medicine, a need for on-going review and deprescribing to be built 
into the process of prescribing, inability to access comprehensive patient records, 
the lack of digital interoperability, and pressure of time 
• cultural: a healthcare culture that favours medicines over alternatives and in 
which some patients struggle to be heard 
 
As well as the physical and mental impact on patients, overprescribing can lead to more 
hospital visits and preventable admissions, even premature deaths. There is also the cost 
in wasted medicines. Overprescribing may disproportionately affect Black, Asian and 
Minority Ethnic communities and those who are more vulnerable, such as the elderly and 
those with disabilities. (See 'The consequences of overprescribing' section.) 
 
Recent initiatives by the NHS have helped stem the growth rate of overprescribing but it 
remains at unacceptable levels. Evidence is limited, but the review estimates that it is 
possible that at least 10% of the total number of prescription items in primary care need 
not have been issued.  
 
We know what will reduce overprescribing: shared decision-making with patients; better 
guidance and support for clinicians; more alternatives to medicines, such as physical and 
social activities and talking therapies; and more Structured Medication Reviews (SMR) for 
those with long-term health conditions. (See 'Responses to overprescribing' section.)  
 
The NHS Long Term Plan is addressing many of the system problems already, such as 
improving digital systems, interoperability and patient records, funding more pharmacists 
in primary care networks (PCNs) to perform Structured Medication Reviews and 
introducing personalised care for patients. Initiatives such as Rethinking Medicine have set 
out the cultural change in medicine that needs to be developed and spread. But to achieve 
a substantial reduction in overprescribing, we need a comprehensive and proactive 







The review therefore proposes: 
 
• systemic changes to improve patient records, transfers of care and clinical 
guidance to support more patient-centred care (see 'The system' section)  
• culture change to reduce the reliance on medicines and support shared 
decision-making (see 'Culture' section) 
• a new National Clinical Director for Prescribing to lead a cross-system 
implementation programme including research and training (see 
'Implementation' section) 
 
The coming year will be critical for the work on overprescribing, with the need to make the 
best use of NHS resources to continue to respond to the impact of COVID-19 as well as to 
deliver important routine healthcare services. This report shows how the development of a 
long-term strategy on overprescribing will help to deliver on these challenges by bringing 
about a fundamental improvement in prescribing systems and culture to support the aims 
of the NHS Long Term Plan. The review proposes to reconvene within a year of 
publication to assess progress. 
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1. This review 
In December 2018 the Secretary of State for Health and Social Care, Matt Hancock, 
commissioned a review to be led by Dr Keith Ridge CBE, the Chief Pharmaceutical Officer 
for England, to evaluate the extent of overprescribing in the NHS and recommend what 
might be done to reduce this problem, particularly in primary care. 
The Review was guided by a Short Life Working Group (SLWG) which brought together 
senior stakeholders from across the healthcare system, together with patient and third 
sector representation. A review team from both NHS England and NHS Improvement and 
the Department of Health and Social Care provided support, including analysis of primary 
care data, along with research commissioned from The Policy Research Unit in Economic 
Methods of Evaluation in Health and Social Care Interventions (EEPRU)1. A summary of 
the Review’s approach and working methods is at Annex A. 
1.1 Patient and professional engagement 
The Review drew on the expertise of ninety healthcare professionals and patient 
representatives. The Review also ran or commissioned: 
• a symposium with around 150 delegates from the medicine, nursing and 
pharmacy professions, from academia and from patient groups and charities  
• a co-design workshop with patients, in partnership with HealthWatch2, the 
campaign group Me and My Medicines3, and the Yorkshire and Humber 
Academic Health Science Network4  
• six engagement events with clinicians 
• 16 focus groups and 20 in-depth interviews with patients and the public from 
an independent research agency  
More on professional and patient engagement can be found in Annex A. 
1.2 Equality and health inequalities 
Promoting equality and addressing health inequalities are at the heart of NHS England’s 
and NHS Improvement’s values. Throughout this Review we have: 
• given due regard to the need to eliminate discrimination, harassment and 
victimisation, to advance equality of opportunity, and to foster good relations 
10 
between people who share a relevant protected characteristic (as cited under 
the Equality Act 2010) and those who do not share it  
• given regard to the need to reduce inequalities between patients in access to, 
and outcomes from healthcare services and to ensure services are provided in 
an integrated way where this might reduce health inequalities 
We have carried out an Equality and Health Inequalities Impact Assessment (Annex B) 
which records our analysis and conclusions. Overprescribing directly affects some 
protected characteristic groups, notably older people, who our evidence shows are much 
more likely to be prescribed multiple and long-term medication and so are more likely to 
experience overprescribing. Other groups are also at heightened risk, including those from 
Black, Asian and Minority Ethnic communities, those living in areas of high deprivation and 
those with a learning disability, and our recommendations directly address these risks.  
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2. The causes of overprescribing 
2.1 In this section: 
• What do we mean by overprescribing? 
• The causes of overprescribing 
• The prescribing system 
• The culture of prescribing  
2.2 What do we mean by overprescribing? 
Put simply, overprescribing is where people are given medicines they don’t need or want, 
or where harm outweighs benefits. It occurs in every healthcare system in the world. It 
occurs in several ways:  
• the patient is prescribed a medicine, when there would have been a better 
alternative. An example of this would be a patient being given a medicine to 
reduce their blood pressure when changes to diet and lifestyle would be more 
appropriate for them 
• the patient is prescribed a medicine which in itself is generally appropriate for 
that condition, but which is not appropriate for the individual patient. For 
example, a patient may have a second condition, such as kidney disease, that 
means the medicine taken for the first one could affect them adversely 
• the patient is prescribed a medicine, their condition changes and the medicine 
is no longer appropriate, but the prescription is not reviewed. For example, 
anti-diabetic medicines prescribed to a patient in their 60s might not still be 
appropriate in their 90s 
• the patient no longer needs or benefits from the medicine, but continues to 
be prescribed it. An example of this would be someone prescribed strong 
painkillers for the short term who is not offered alternative support to assist 
with pain management 
When a clinician issues a prescription, it is usually because they genuinely believe that it is 
something the patient needs. Overprescribing is rarely the result of a faulty diagnosis. As 
we shall see, the extent of overprescribing is a result of weaknesses in the healthcare 
system and culture, not the skills or dedication of individual healthcare professionals.  
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It is not easy to know the true extent of overprescribing, but the review has looked at the 
available evidence and our best estimate is at least 10% of the current volume of 
medicines may be overprescribed (though this will be less than 10% by value). 
There are over 1.1 billion prescription items dispensed each year in primary care and the 
community in England,5 which indicates the scale of the problem. (This estimate is 
discussed further in 'Our strategy' section.) 
2.3 The causes of overprescribing 
Most of us are familiar with the prescribing process. We see a healthcare professional and 
describe our symptoms. They diagnose and prescribe a medicine which we collect from 
the pharmacy. Depending on the condition, it may clear up straight away. In some cases, 
particularly as we get older, we may need to keep taking the medicine, and for 
convenience we will receive a repeat prescription for a set period without needing to see a 
healthcare professional each time. 
But what can seem so simple can be very complex, as those with multiple or long-term 
conditions know all too well. People don’t always see the same clinician. As well as GPs, 
there are consultants and specialists in hospitals, and some nurses, clinical pharmacists, 
allied health professionals, health visitors and dentists also prescribe medicines. This has 
improved patient care but created new challenges such as managing prescribing records 
across multiple systems, ensuring reviews are holistic and managing clinical interactions 
well. 
“The GPs are fine – it’s the co-ordination between all the different 
consultants and across the county boundary.” 
Prescribing itself is far from straightforward. Choosing the right treatment depends on 
knowing the patient’s previous medical history and current conditions and treatments; and 
also their wider lives – anything from stress at work to damp or mould in their home. 
Clinicians need to understand the person, not just the condition. This understanding 
depends on building up trust, so that patients can overcome anxiety, open up about their 
needs, fears and cultural or other preferences, and ask questions about their condition or 
treatment.  
“It would help a lot if they had a better understanding of culture and 
upbringing – this is a general society issue, not just about the NHS.” 
Despite this complexity, most of the time, this process works. Every day, people get the 
medicines they need, and their health and wellbeing is improved as a result. Essentially, 
this is because clinicians are able to diagnose quickly what is wrong, and agree the best 
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course of treatment with the patient – though many clinicians, like patients, would like to 
have more time for this than the standard appointment allows. 
For this review, we spoke to over a hundred individual patients and most were full of praise 
for clinicians and for the NHS. However, many could tell of experiences that fell short of 
the ideal:  
• feeling they were not listened to, so the prescription didn’t really address their 
issues or their preferences 
• taking medicines without really understanding why, or knowing what the risks 
or side effects might be 
• not receiving the support or answers they need when they have issues with or 
questions about their medicines 
• being prescribed medicines such as antidepressants, where an alternative 
such as a talking therapy would have been more appropriate 
• being prescribed medication by different clinicians, with no co-ordination or 
joining up of treatments or patient records 
• taking medicines that no longer seem to work, or which are causing troubling 
side-effects, but not being confident to talk to the doctor about it 
The clinicians we heard from were similarly frustrated with the current system: 
• they often didn’t feel they’d got to the root of the patient’s problem, and so the 
treatment they offered was dealing more with symptoms than causes 
• they would have liked to refer a patient for a non-medical treatment, but this 
was not available or the waiting time was too long  
• they couldn’t be sure how the treatment they were prescribing would fit with 
care being provided by other healthcare professionals 
• other clinicians had prescribed medicines, but they didn’t know why because 
the reason wasn’t recorded on the patient’s records 
 
Today’s clinician can deploy a vast number of treatments that doctors would not have 
dreamed of at the inception of the NHS in 1948. But it is in part because they can be, or 
are perceived to be, so effective, that the tendency is to prescribe more drugs to more 
patients. In 1996, the number of prescription items dispensed in primary care and the 
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community in England was 10 per head6. By 2016, it had doubled to 20,7 as shown in 






Figure 1: The Average Number of Prescription Items per Head of Population by 
year 1994-2019. 
There are more people taking the same medicine for months or years to treat a long-term 
condition. Repeat prescriptions make up around three-quarters of all prescription items. 
They can be left without review for long periods, increasing the risk of overprescribing. 
There are also more people taking multiple medications. Currently, around 15% of people 
in England are taking five or more medicines a day, with 7% on eight or more (see Annex 
E). In some cases, people are taking one medicine to deal with the side effects of another. 
Side effects are a major cause of overprescribing, because what may be the right 
treatment for someone with a single condition, may need to be adjusted or stopped for 
someone who has multiple conditions. One medicine may interact negatively with another. 
There is also the cumulative burden on the patient’s metabolism – and on their quality or 
life – of taking so many different medicines each day. 
2.4 The prescribing system 
The Review has identified a series of factors in the healthcare system that contribute to 
overprescribing. All these tend towards more prescribing, and longer periods of 
prescribing, often at higher doses. These include: 
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Patient care records. Where these are not comprehensive or are not available to 
the clinician providing care to the patient or the patient themselves. Although 
Electronic Health Records are becoming more common and effective, there are 
issues with exchange of information between primary and secondary care, or with 
giving full access to all those providing care. As well as GP prescriptions, many 
people receive medicines from other providers including hospitals, not all of which 
have electronic systems for recording prescribing. If the computer systems in each 
sector are not linked, prescribers may be unaware of other medicines prescribed. 
Also, patients may purchase medicines over the counter, which can sometimes 
affect how prescribed medicines work. In most instances, patients are unable to 
add information of this kind, or on side effects they have experienced, to their 
records. 
“I don’t think GP surgeries and pharmacists talk enough between each 
other. They should be more joined up.” 
Hospital discharge letters. These are an essential link between different 
providers of care – typically a hospital consultant and a GP – but sometimes those 
who need the information, such as those providing a care package for a patient 
being discharged from hospital – do not receive the letter in time, or at all. This can 
lead to errors, including inadvertent reintroduction of discontinued medicines. 
Similar problems arise with other letters communicating clinical decisions or 
information, such as clinic letters between specialists and primary care. There are 
also limited mandatory fields on discharge letters for medicines so full information 
may not be supplied.8 
Clinical indications. One clinician may be reluctant to withdraw medication which 
has been prescribed by another, particularly if the latter is a specialist or they do 
not know why it was prescribed. Discharge letters, clinic letters and the electronic 
health record should record the ‘clinical indication’ or rationale for prescribing the 
medicine, but this does not always happen.9  
Transfer of care. When a patient’s care transfers between services there is an 
increased risk of medication errors. In 2015 a NICE report suggested between 
30% and 70% of patients may have experienced an error or unintentional changes 
to their treatment when care was transferred.10 
 
Treatment guidelines. Evidence and guidance on rational alternatives to 
medicines is also much less extensive and rarely integrated properly into 
treatment or prescribing guidelines. Guidance on prescribing does not routinely 
explain when and how to stop a medication or regularly review its long-term 
benefit.  
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Clinical evidence. There is a marked imbalance between the evidence that 
supports the prescribing of medicines and the evidence for reducing or stopping a 
medication. For example, clinical trials typically involve people between the ages 
of 18 and 64, which means that the effects of the medicine on older patients is less 
well understood.  
Alternatives. Medicines can also ‘crowd out’ alternatives such as clinicians giving 
advice on diet or exercise or access to physiotherapy or counselling. These may 
be less accessible or affordable, particularly in contrast to medicines that can be 
provided quickly or easily in primary care and which are free for the patient in 
around 90% of cases. 
“If I exercised, I know it would have benefits, but I’m just not motivated to 
do so.” 
Repeat prescriptions. When managed correctly, repeat prescribing reduces the 
need for appointments and ensures continuity of medicines. However, because 
repeat prescriptions can be issued for months, even years, it is important they are 
subject to effective review. There is no standard approach to processing repeat 
prescriptions within GP practices. Further, GP practices can receive over 200 
requests for repeat items a day, and GPs can spend up to two hours a day dealing 
with repeat prescriptions11, and there is a risk of this becoming a tick-box exercise. 
Also, many patients find the system complex, inflexible and unreliable and it can 
lead to stockpiling medicines or ordering everything on their prescription when 
they only need a few items. These may end up being thrown away, or given to 
others or misused. 
“They give you more than you need. I can take up to three tablets with one 
of my medications, but I don’t always need to, so I end up with extra boxes 
all of the time.” 
Single reviews. Medication needs to be reviewed to make sure it is still effective 
and safe, but quality incentives in general practice often focus only on a single 
condition, where what patients want and need is a holistic review of their care.  
 
“If medication is not reviewed, you could be on the wrong thing for the rest 
of your life.” 
Good for you, good for us, good for everybody 
17 
2.5 The culture of prescribing 
Today’s prescribing culture includes a strong sense of ethics, a commitment to knowledge 
and evidence and a dedication to patient care. However, in some cases there is still a 
paternalistic tendency to believe that ‘doctor knows best’ and to treat the illness not the 
person, and a belief in the primacy of medicines to treat people’s ills. Pressure for change 
is coming from within the healthcare professions, as well as from patient groups, as shown 
by the number of clinician-led initiatives such as Rethinking Medicine.12 
“You give the GP the facts and say what is wrong with you and your role is 
to take them as instructed.” 
The ‘biomedical model’13 of healthcare encourages prescribing following single-disease 
guidelines, often without consideration of alternatives to medicines and without sharing 
decision-making with the patient, and with a resistance to stopping or altering medication 
initiated by another clinician. Many patients do not feel that they experience a 
compassionate, coordinated service that pays enough attention to their individual needs, 
assets, values, preferences and priorities.14  
“I felt I was pressured by the doctor to take amphetamines [for ADHD] and 
they didn’t explain enough about the side-effects.” 
The biomedical model can influence patients too. Some say they have experienced 
anxiety – even a feeling of abandonment – when there was no suitable medication 
available for them. And we have seen with antibiotics (notwithstanding recent 
improvements in prescribing these important medicines), when patients expect, or press 
for, medication, clinicians may be influenced to prescribe when it is unlikely to be helpful or 
appropriate.  
“Some doctors are not strong enough to say ‘I am not prescribing that’.” 
But this is not how the healthcare professions or patients want it to be. Just as with poor IT 
or the lack of alternative treatments, clinicians are working within a culture that lets them 
and their patients down, but which is hard to change.  
The Review has identified a series of factors in prescribing culture that contribute to 
overprescribing and which will need to be addressed if we want patients and clinicians to 
be equal partners. These include: 
Equality. Patients report that the unspoken signals given by busy clinicians during 
appointments – such as not looking up from their keyboard – discourage them 
from asking the questions that might reassure them or help them to manage their 
own health better. Similarly, discharge letters symbolise an old-fashioned way of 
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thinking about the equal relationship of the clinician and the patient, because they 
are not addressed to the patient, but to another clinician, in effect discussing the 
patient and their treatment ‘over the patient’s head’. Further, the letters are often 
written using medical abbreviations and jargon, making them very difficult for most 
patients to understand and act on. 
“I just do what the doctor tells me.” 
“You take it for granted that the GP knows what he’s doing.” 
Information. Many patients we spoke to were cautious about using the internet to 
research their conditions and wanted more trusted and accessible information. 
Though some were positive about leaflets produced for patients about specific 
conditions, they were particularly critical of patient information leaflets contained 
within boxes of medication, saying they were too detailed, too alarming and 
designed to ‘cover the backs’ of the manufacturers. 
“The NHS website is pretty good. You can trust that.”  
“The leaflets are scary. The side effects are worse than the problem.”  
Knowledge. There is a widespread assumption that medicines are more effective 
than other strategies to manage health and wellbeing (such as keeping active, 
eating a healthy diet, connecting with community activities or physiotherapy). Both 
the general public and healthcare professionals over-estimate the benefits and 
underestimate the harms of medical interventions.15,16 
“Sometimes I have no clue what they’re talking about. I just take whatever 
medications they give me.” 
Confidence. We heard from patients who did not feel they were on the right 
medicines, but who did not know what to do or were reluctant to bother their 
clinician or ask further questions. Patients need to be reassured that they should 
contact their clinician if their condition changes or their medication no longer feels 
right.  
Challenge. Tackling overprescribing depends on continuing to develop a culture 
of openness to challenge within healthcare. Many patients report not fully 
understanding their discussions with clinicians, particularly when they are anxious 
or upset or where language or cultural barriers exist. Many also feel reluctant to 
question the decisions of clinicians and so will accept or continue with a 
prescription, even when they do not think it is helping – or may simply stop taking 
the medicine but will not let the clinician know. Clinicians too can be reluctant to 
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challenge their colleagues, or seniors, or specialists, and some clinicians do react 
negatively if a pharmacist or another clinician queries a prescription. We need a 
clinical culture that is accepting of questioning and, if necessary, of challenge, 
where it is not seen as a criticism of the prescriber but a means of facilitating 
discussion and ensuring patient safety. 
“I ask, but I’ve felt so put down that I just don’t ask any more.” 
“Sometimes you’ve got to be prepared to fight your own corner.” 
There are numerous examples of significant advances in the treatment of disease that are 
due to the efforts of the pharmaceutical industry. However, some activities of the 
pharmaceutical industry can influence both the prescribing habits of clinicians, and the 
demand for medicines from patients. In the USA, direct advertising of prescription 
medicines to patients is thought to have a major impact on demand for medicines, and the 
role of the pharmaceutical industry in overprescribing of pain-relieving medications, such 
as opiates, has been criticised and led to extensive litigation. In the UK, direct advertising 
of prescription medicines to the public is not permitted. It should stay that way. The UK 
pharmaceutical industry has engaged in initiatives to optimise medicine use, including 
reducing problematic polypharmacy, but concerns remain about pharmaceutical 
sponsorship of professional education or patient representative groups, and how 
sometimes clinicians undertaking research sponsored by the pharmaceutical industry are 
also involved in the development of clinical guidelines.  
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3. The consequences of overprescribing 
3.1 In this section: 
• The patient experience 
• Patient harm  
• Problematic polypharmacy 
• Healthcare resources 
3.2 The patient experience 
Medicines are a matter of life or death for many people, and bring huge benefits to many 
millions more. But the more medicines someone takes, the more likely they are to 
experience side effects and interactions between their medicines. If they are taking a 
medicine for which there is a better non-medicine alternative, this may impact on their 
health and quality of life. There can also be a burden simply in taking and managing their 
medicines, particularly for those on multiple medication, leading to medicines not being 
taken as intended. Some people simply find it all too much and stop taking their medicine 
altogether. 
These burdens weigh particularly heavily on older people, who are more likely to be taking 
multiple medications. And as people get older, so the body’s reaction to medicines 
changes, which means the dose might need to be changed or the medicine stopped 
altogether. But sometimes that does not happen, and patients can suffer adverse effects 
such as falls due to low blood pressure or low blood sugar. This can have very real and 
negative impacts on older people’s day-to-day functions and activities. 
“I take eleven medications now after having a heart attack twelve years 
ago. Some of the tablets deal with the side effects of other ones.” 
3.3 Patient harm 
An adverse drug reaction (ADR) is an unwanted or harmful effect of a medicine: what 
patients tend to call side effects. ADRs are not uncommon and, not surprisingly, the 
chances of experiencing an ADR go up, the more medicines you take. ADRs are thought 
to occur in 10-20% of hospital in-patient admissions.17 A person taking ten or more 
medications is 300% more likely to be admitted to hospital because of an ADR18.  
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“I was given tablets for blood pressure and they affected my anxiety 
levels.” 
As an example, some classes of medicines, such as those to reduce blood pressure, can 
increase the risk of falls amongst the frail and elderly, often leading to broken bones. This 
will often mean a long hospital stay and extended recovery, and may result in the patient 
experiencing on-going pain, and a loss of mobility, confidence and independence. 19   
Around 6.5% of hospital admissions are caused by adverse effects of medicines. This 
rises to up to 20% in the over 65 age group17. Two thirds of medicines-related hospital 
admissions are considered preventable.20 
Some prescribed medicines create a risk of dependency or can be difficult to stop taking. 
This can lead to overprescribing, as identified in the Public Health England (PHE) 
Prescribed Medicines Review Report21.  
“For addictive drugs, you should be called in for a review. You might not 
need them, or you might be able to get a lower dose.” 
3.4 Problematic polypharmacy 
Problematic polypharmacy is one of the main consequences of overprescribing. People 
who are taking multiple medicines are more likely to be older, have worse health 
conditions, be taking medicines for longer, face more difficult decisions about treatment 
and find the cumulative burden of their medication harder to bear than the average. For 
this cohort, it is also harder for clinicians to spot problematic or unnecessary prescriptions, 
as the cumulative effect can be difficult to evaluate without more specialist training.  
“In some cases, they just respond to what you tell them and give you 
medication for it. I don’t think they take account of the other conditions that 
you have.” 
Polypharmacy – the medical term for taking multiple medicines – is not of itself a bad 
thing. For instance, by following the National Institute for Health and Care Excellence 
(NICE) guidance on post-myocardial infarction,22 a patient will be prescribed five 
medicines, which is within one definition of polypharmacy.  
However, studies of inappropriate or problematic polypharmacy23 reveal some of the 
causes and consequences of overprescribing. In 2009, the Care Home Use of Medicines 
Study (CHUMS)24 report highlighted deficiencies in the prescribing, handling and 
administration of medicines. A report in 2011 by Age UK and the Health Foundation25 
reinforced the findings from CHUMS on reporting excess and inappropriate prescribing, 
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lack of a structured medication review, and a lack of resident involvement in decisions 




























Polypharmacy data also points to potential links between overprescribing and health 
inequalities. Polypharmacy increases with relative deprivation (as shown in Figure 3) and 
the rate of those on two or more medicines is 2.8 times greater in the most deprived areas 
compared to the least deprived. Even allowing for age and sex, those living in the most 
deprived areas are much more likely to be taking eight or more medicines. We cannot say 
what proportion of this polypharmacy is problematic, but the data is concerning: for 
example, almost two in three people who are taking eight or more medicines are on at 












Figure 3: Prescribing rate and rate of patients on eight or more medicines by IMD 
decile, standardised by age and gender.  
 
 
Similarly, from a sample in June 20191, we can see that a higher proportion than average 
of those who identify as Asian/Asian British are on eight or more medicines (as shown in 
Figure 4). Again, we cannot say from this data what proportion of polypharmacy amongst 
Black, Asian and Minority Ethnic populations is problematic, only that the data suggests 




1 The sample is broadly representative of ethnicity in the population at large but we don’t know the extent of 
any sampling bias that might mean, for example, that the Asian people in the sample need more medicines 




Figure 4: Age-standardised proportion of patients on eight or more medicines, by 
ethnicity. 
3.5 Healthcare resources 
As well as the directly negative effects for individual patients, overprescribing is also a 
waste, in that the National Health Service is buying medicines and giving them to people 
who don’t need or want them. The Medicines Value Programme has demonstrated how 
spending can be reduced without affecting the quality of care provided to patients, for 
example by identifying where medicines should not be routinely prescribed or where 
patients can obtain items ‘over the counter’ from pharmacies. With overprescribing, given 
that the NHS primary care medicines budget is around £9.2 billion a year,26 the potential 
savings and reductions in waste are very significant. Tackling overprescribing will also 
bring savings in preventing avoidable hospital admissions and the use of other services. 
Our estimates of overprescribing imply that millions of packets of medicine are wasted 
each year, which consumes energy, plastics and other resources from manufacturing via 
distribution and storage to disposal, in the UK and internationally. For example, the 
production and use of some medicines can generate significant greenhouse gas emissions 
and so contribute to climate change. Reducing overprescribing will help the NHS fulfil its 
commitment to become carbon net zero.27 
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4. Responses to overprescribing 
4.1 In this section: 
• Medicines optimisation 
• Patient-level medicines optimisation 
• Structured medication reviews 
• Medicines reconciliation 
• Deprescribing 
• Variation and data analytics 
4.2 Medicines optimisation 
 
Overprescribing is not a new problem and a lot of great work has been done to address 
the issue, on which this review aims to build. (Examples of case studies are in Annex C, 
and key papers are in Annex D.) Healthcare professionals and NHS managers have been 
developing strategies for many years, and together with scientists, policymakers and 
patient representative groups have contributed to building up our understanding not only of 
the problem, and its consequences, but also of ways to tackle it.  
The key to stopping overprescribing is medicines optimisation: ensuring that patients are 
prescribed the right medicines, at the right time, in the right doses.28 In some cases, 
medicines optimisation may lead to a patient being offered additional medication, or having 
their dose increased, but it also provides a framework for reducing and stopping 
overprescribing.  
Medicines optimisation is based on four principles:  
• aim to understand the patient’s experience 
• evidence-based choice of medicine 
• ensure medicine use is as safe as possible 
• make medicines optimisation part of routine practice 
26 
 
Alongside these four principles, there is the overall aim of better patient outcomes, and the 
foundation that medicines optimisation must be centred on the needs and preferences of 
the patient and depends on effective measurement and monitoring. Supported by the 
NICE Quality Standard for Medicines Optimisation,29 this can be best captured in the 
diagram in Figure 5.   
 
Figure 5: The key principles of medicines optimisation.30 
 
From the 1990s, there have been several initiatives to help promote medicines 
optimisation and reduce overprescribing across the primary care system. To mention a few 
from within the NHS: 
• pharmaceutical advisors in Clinical Commissioning Groups (CCGs) have 
worked with prescribers to help ensure that patients benefited from therapeutic 
advances, but in a manner that is safe and cost-effective; 
• medicines optimisation teams in CCGs have worked with GP practices to 
improve the safety, efficacy and value of the prescribing within the practice; 
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• Regional Medicines Optimisation Committees31 or RMOCs have been 
established to bring together decision-makers, healthcare professionals and 
patients, as well as Area Prescribing Committees in primary care, to reduce 
unwarranted variation and improve outcomes and value from medicines use; 
• the Medicines Value Programme32 includes producing guidance for CCGs 
on optimising the use of medicines; 
• the Academic Health Science Network Medicines Optimisation 
Programme33 which has worked to improve transfers of care around 
medicines, problematic polypharmacy, medicines errors and shared decision-
making; 
• the NHS Business Services Authority’s polypharmacy prescribing 
comparators34 and other NHS BSA prescribing dashboards to support CCGs 
to reduce unwarranted variation in primary care prescribing; 
• NHS RightCare35 which involved teams working collaboratively with systems 
to review indicative data on prescribing to identify opportunities to reduce 
unwarranted variation and improve population healthcare on a wide range of 
conditions including respiratory illnesses and diabetes. 
“GPs have got better. They won’t give you medicines they don’t think you 
need.” (G2) 
There are also initiatives aimed at tackling overprescribing for specific classes of medicine. 
For example, the UK’s first five-year national action plan on antimicrobial resistance 
(AMR), from 2013-18, was an extensive programme and showed that a significant 
reduction in the prescribing of antibiotics in primary care can be achieved as can be seen 
in Figure 6.36 
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Figure 6: the annual rate of antibiotic prescribing per 1,000 people, 2014-19. 
 
There are similar examples of progress with specific groups of patients. For example, the 
Stopping Overmedication of People with a Learning Disability, autism or both 
(STOMP) initiative37 targets the overuse of psychotropic medications for people with a 
learning disability, autism or both. If children or young people do need psychotropic 
medication, it should be seen as the last resort. Medication should be regularly reviewed to 
make sure it is still the right thing for them and they do not stay on the medication for 
longer than is necessary. The Supporting Treatment and Appropriate Medication in 
Paediatrics (STAMP) initiative38 aims to make sure that children and families can access 
other treatment and support when children display behaviours that challenge, for example 
Positive Behaviours Support or other therapeutic support.  
4.3 Patient-level medicines optimisation 
Pharmacists are also working more closely with other prescribers and individual patients. 
For example, the Northumbria SHINE quality improvement project found that clinical 
pharmacists undertaking structured medication reviews within a shared decision-making 
framework were able to safely reduce prescribing by 17.4% through stopping medicines 
that were no longer indicated or were causing harm. 
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In 2015, NHS England commissioned 50 Vanguard39 sites to test new care models; and 
the sites where pharmacy professionals were integrated into the wider multidisciplinary 
team showed medicines optimisation benefits, in particular to patients in care home 
settings.  The care homes work showed pharmacists reviewing medicines improved 
patients’ quality of life by reducing unnecessary use and bringing down emergency 
admissions, with less time spent in hospitals. This approach also led to meaningful savings 
in unnecessary prescribing costs of £249 per patient in one pilot over a year.   
Initiatives such as these led to the national commissioning of two complementary 
programmes: Clinical Pharmacists in General Practice (CPGP) in 2016 and Medicines 
Optimisation in Care Homes (MOCH) in 2018.40  Both programmes showed that 
embedding clinical pharmacists in patient-facing roles in primary care improved quality of 
care, reduced harm from medicines and increased efficiencies. The MOCH programme 
further highlighted the impact pharmacy technicians could make on medicines optimisation 
and management.  Both roles have now been successfully embedded into the new 
Primary Care Networks’ (PCNs) Additional Roles Reimbursement Scheme.41 Currently 
around 2,000 clinical pharmacists and pharmacy technicians, funded by NHS England and 
NHS Improvement are working in teams in primary care networks, and thousands more 
are due to be appointed by 2024 under the NHS Long Term Plan. Each receives 18 
months of additional clinical training to enable them to work safely with patients to review 
medicines use and support deprescribing where appropriate.  
4.4 Structured Medication Reviews 
A Structured Medication Review (SMR) is a comprehensive review of all a patient’s 
medicines and detailed aspects of their health. It is a clinical intervention approved by 
NICE and delivered via a shared decision-making conversation with a patient that ensures 
their medication is working well for them. If problems are identified, options are considered 
such as changing the dosage, finding additional support or stopping a medicine. The 
patient is involved throughout the discussion and in any changes to their medication. This 
makes SMRs an ideal tool to help people with problematic polypharmacy. This is different 
to the check-ups or other reviews that clinicians conduct with those with long-term health 
conditions and which may involve their medicines. 
4.5 Medicines reconciliation 
Medicines reconciliation10 identifies anomalies in what the prescribing records says a 
patient should be taking, compared to the medicines the patient is in fact receiving and 
taking. As well as improving patient safety and reducing harm from medicines, this also 
provides a valuable opportunity to identify those who may benefit from a structured 
medication review, for example because they are taking multiple medication or are 
vulnerable or have been taking their medication incorrectly or not at all. 
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4.6 Deprescribing 
Prescribing can be seen as a form of problem-solving, with a medical condition as the 
problem and a medicine as the solution. But more often than not medicines can only 
manage a condition, not cure it, and the wider needs and preferences of the patient may 
change. 
“I was taking folic acid tablets, but I stopped after six months as the GP 
said I could get the same benefits from eating more vegetables!” 
“I was given anti-depressants for five years and no one checked on me.” 
Stopping a medication may be just as challenging in terms of weighing the benefits or 
providing support as starting it. Deprescribing seeks to apply best practice in prescribing to 
the process of stopping a medicine. It needs the same skill and experience from 
prescribers, and the same level of support from pharmacists, and from guidance, data and 
insight, even from the pharmaceutical manufacturers, to get the best results. And just as 
with prescribing, it should place patients at the centre of the process, to ensure medicines 
optimisation.  
4.7 Variation and data analytics 
There are significant variations in the way in which certain medicines are prescribed in one 
geographical area compared to another. For example, prescribing rates for antibiotics 
differ by as much as two and a half times between one part of the country and another. 
There may be good reasons for such differences, and higher rates of prescribing are not 
necessarily a bad thing. For example, if one CCG is more likely to prescribe a medication 
than another, this may indicate overprescribing, or may indicate better patient care that 
other areas could learn from. What we can say is that identifying unwarranted variations in 
prescribing can help ensure medicines optimisation and improve patient safety. This is part 
of the work of the Regional Medicines Optimisation Committees, and the Getting It Right 
First Time (GIRFT)42 programme.   
The more we know about what is actually being prescribed and dispensed, the more we 
can spot trends and unwarranted variation. Better use of data has led to better insights into 
overprescribing, and how to tackle it more effectively. 43 For example, the NHS Business 
Services Authority and Wessex AHSN Polypharmacy Prescribing Comparators34,44 were 
developed to help CCGs and general practices identify patients most likely to be exposed 
to the risks associated with taking multiple medicines or certain combinations of 
medicines. The comparators enable GP practices and CCGs to: 
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• see variations in prescribing across GP practices, and within and across 
CCGs  
• identify if polypharmacy is an area to be investigated in the practice or CCG 
• help prioritise potential areas of activity and better target areas where 
improvement is needed to reduce the risk to patients 
 
In addition, data analytics and analysis can directly assist prescribers by identifying 
individual patients who may be at risk of overprescribing. This allows the prescriber to 
review their case or ask the patient to take part in a medication review. The NHS Business 
Services Authority’s ePACT 2 system gives authorised users access to prescribing data at 
a variety of levels, from data summaries to individual prescription items. Data can be 
exported to form reports and dashboards and used to view patterns of prescribing at 
patient level.45  
More recently, sophisticated data science techniques have been applied to prescribing 
data, revealing even more insights, with the leading group being the EBM DataLab at the 
University of Oxford. Their OpenPrescribing tool is now widely used across the NHS.46 But 
the challenge remains of how to help prescribers and those conducting SMRs to make full 
use of this new abundance in data and insight. 
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5. Our strategy 
5.1 In this section: 
• NHS long term plan 
• Personalised care and shared decision-making 
• Pharmacists and medicines optimisation 
• Medicines reconciliation 
• Social prescribing 
• Our ambition 
5.2 NHS Long Term Plan 
 
Overprescribing is a major issue in healthcare with a serious impact on clinicians, patients 
and resources. Trends in healthcare have the potential to exacerbate the problem because 
there will be more people living longer and coping with multiple conditions, and with their 
care shared between more clinicians and services. As we look to learn from and respond 
to the effects of COVID-19, we need to be ready to do things differently – as with the 
accelerated progress in in electronic prescribing and telemedicine resulting from the 
pandemic. It’s important therefore that we act now on overprescribing through a 
comprehensive and coordinated strategy that everyone can buy into. 
The NHS Long Term Plan (LTP)47 was developed to shape the development of the NHS 
over ten years from 2019, covering principles and priorities, ways of working, investment in 
people and systems and the deployment of healthcare resources. It is a framework, with 
specific reviews, plans and programmes that further flesh out the strategy and provide the 
detail of implementation. This Review was launched just before the LTP was published, 
and therefore we have used it as the foundation for our strategy to tackle overprescribing. 
The LTP also sets out initiatives in areas such as making better use of data and digital 
technology and improving electronic health records which are vital to tackling 
overprescribing. Part of the task of the Review has been to identify where further action is 
needed to ensure that this investment will grasp the opportunities to reduce 
overprescribing. Our strategy for tackling overprescribing therefore combines two strands: 
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• acknowledgement of where the LTP is already delivering directly on the 
overprescribing agenda, to show how this will help deliver our strategy (this 
section) 
• recommendations for where we need to go further to build on the LTP to tackle 
weaknesses in the prescribing system (Section 6) and culture (Section 7); and 
to develop key areas that support implementation such as research and 
training (Section 8) 
The LTP seeks to change the culture within healthcare, and two of its deliverables – 
personalised care and shared decision-making – will help improve the culture of 
prescribing. It also directs more resources into primary care, including expanding 
medicine optimisation, Structured Medication Reviews, medicines reconciliation and 
social prescribing. All these are discussed below. 
5.3 Personalised care  
This has been shown to help reduce health inequalities, giving people choice and control 
over the way their care is planned and delivered based on ‘what matters’ to them and their 
individual strengths, needs and preferences. It tailors health information to people’s level 
of health literacy and increases peoples’ capacity to use health information effectively and 
to identify the issues that most affect their wellbeing. The Comprehensive Model of 
Personalised Care48 draws on and is supported by the Personalised Care Institute for 
training healthcare professionals and the National Academy for Social Prescribing to 
provide development and support to teams in the NHS. The LTP will extend personalised 
care to an additional 2.5 million people by 2024. 
“You know your body the most, especially around your pain levels.” 
“I feel like if you just go to one GP for a very long time then you have that 
connection and relationship, so they are very attentive to you. But when I 
was referred sometimes, I felt they could listen better or treat me better.” 
5.4 Shared decision-making 
 
A better prescribing culture, together with improved systems for information and support, 
should allow prescribers and patients to come to a shared decision about a course of 
action, based on the evidence and on the preferences of the individual. Shared Decision 
Making (SDM), which is a key part of the Comprehensive Model of Personalised Care, is a 
collaborative process between a clinician and a patient, where the clinician supports the 
patient to reach a decision about their treatment that is right for them. It brings together the 
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clinician’s expertise about treatment options, evidence, risks and benefits and the patient’s 
circumstances, goals, values and beliefs. 
“We have more responsibility than our parents had for taking their 
medication. We are less deferential today, which is a good thing. Seeing a 
doctor these days is more about having a discussion with them.” 
“It feels like a joint thing and we talk.” 
The Review heard from many people who welcomed the greater availability of online 
consultations resulting from the COVID-19 pandemic, particularly because of their 
convenience. As this change is likely to continue, the impact on the quality of diagnosis 
and prescribing, and on shared decision-making, will need to be monitored. 
We heard in the Review from people who did not want to take a more active role in 
decisions about their care, or who felt they did not have the capacity to do so. One of our 
recommendations is that there should be more information and encouragement for people 
to help make shared decision-making a reality. But this should be empowering, not 
compulsory: no-one will be asked or required to take on more responsibility for decisions 
about their care than they are comfortable with. Equally, any system of shared decision-
making must take into account the cognitive functioning of people, not least in older 
patients, and the role of carers in this regard becomes critical. 
5.5 Pharmacists and medicines optimisation 
The LTP will support expansion of pharmacy professionals in Primary Care Networks in 
England, funding the deployment and specialist training of thousands of clinical 
pharmacists and pharmacy technicians. By 2024, each of England’s over 1,200 PCNs 
could have as many as seven clinical pharmacists or pharmacy technicians to support 
improvements to prescribing and medicines safety to benefit patients. This will allow 
clinical pharmacists to provide much more effective support to GPs and other prescribers 
across the practices in the PCN. In particular, they will be able to provide comprehensive 
reviews of the medication regimes for the most vulnerable patients through Structured 
Medication Reviews. 
“Anything that means you don’t need medication is a good thing. The 
medicine might work, but your liver and kidneys are not going to be 
happy.” 
The expansion of clinical pharmacist-led structured medication reviews will improve care, 
particularly for specific groups such as those living in care homes, those with complex and 
problematic polypharmacy, and those with severe frailty. These groups are likely to include 
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patients with multiple long-term conditions, in particular respiratory disease and 
cardiovascular disease. The service guidance for SMRs and medicines optimisation in 
PCNs also sets out how reviews can reduce unnecessary hospital admissions and events 
such as falls and help the £20.9 billion NHS medicines budget go further by reducing the 
proportion of medicines that are not taken by patients as prescribed.26  
The LTP also promotes medicines optimisation to reduce inappropriate prescribing of (a) 
antimicrobials, (b) medicines that can cause dependency, (c) higher-carbon inhalers and 
(d) nationally identified medicines of low priority. To help achieve these outcomes longer-
term, pharmacy and medical leadership at Regional and Integrated Care System level 
must actively work with their PCNs, CCGs and hospitals, to share expertise and lessons 
learned: for example, to integrate national-level programmes, such as the AMR action plan 
and optimising medicines in people with learning disabilities and/or autism, including 
implementing STOMP, into their local implementation of SMRs, medicines optimisation 
and related work. 
Most CCG Medicine Optimisation teams have particular strengths in different areas, such 
as engagement with their local networks, or using data to identify problems, but their 
impact has been hampered by the lack of formal structure. There is no textbook or 
standard procedure for their work, while reflection and insight is exchanged more through 
‘grey’ literature such as conference presentations than academic studies, and there is a 
lack of formal core competencies, training and targeted professional development. 
5.6 Medicines reconciliation 
NICE guidance10 recommends that medicines reconciliation processes should be in place 
for all persons discharged from a hospital or another care setting back into primary care 
and the act of reconciling the medicines should happen within a week of the patient being 
discharged. 
To implement these recommendations requires health and care professionals across 
hospitals, PCNs and community pharmacy to work together much more effectively. Under 
the LTP, Academic Health Science Networks have been supporting NHS trusts to put in 
place communication systems with the patient’s community pharmacy, through their work 
on Transfers of Care Around Medicines (TCAM)49. This involves patients who have been 
identified as being at risk from adverse effects or needing support with their medicines on 
discharge, being referred for advice and support from their usual community pharmacy. As 
a result of the TCAM work, NHS England and NHS Improvement is introducing the NHS 
Discharge Medicines Service from January 2021. This will allow secondary care clinicians 
to refer patients to a local community pharmacist to review medication changes at 
discharge, to reduce harm from medicines that can occur at transfers of care, so ensuring 
better patient outcomes and reducing hospital readmissions. 
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5.7 Social prescribing 
People’s health is influenced by a range of social, economic and environmental factors 
such as housing, economic resources, pollution, health behaviours and diet. Often, 
medicines only deal with symptoms, and do not tackle the underlying causes of illness or 
effect a cure. Medicines are sometimes prescribed where the patient would benefit from 
other forms of advice and support to tackle or alleviate these underlying causes.  
“I was sent to a COPD ‘breathe easy’ clinic. It was absolutely brilliant. It 
helped me to reduce from four to two inhalers over six weeks.”  
Prescribers have always known and acted on this. During the review we heard from many 
people whose prescriber had recommended changes in diet, ways to reduce stress or 
increase exercise, or recommendations to take part in group activities. Sometimes this 
was presented as a direct alternative to a medicine, for example, discussing changes in 
diet to reduce cholesterol as an alternative to a prescription for statins. But prescribers 
have not had systematic guidance and support. For example, 40% of GPs say they would 
refer patients if they had more available information about services.50 
“My consultant told me that I needed to exercise for 30 minutes every day. 
So I got myself a dog. It’s the biggest positive thing I’ve done.” 
“At my GP surgery there is someone to help you with benefits and advice.”  
Increasing the uptake of social prescribing requires prescribers to have a better evidence 
base to draw on, including treatment guidelines that set out these alternatives alongside 
the medication options. Under the LTP, there are hundreds of social prescribing link 
workers now based in primary care networks to build and maintain a set of options 
available locally, integrated with national resources such as health apps. The patient may 
be referred to the social prescribing link worker by their GP or another prescriber to 
discuss specific options and preferences, and the link worker can then arrange for the 
patient to participate in activities. Alongside the prescriber, social prescribing link workers 
can also provide advice, support and encouragement.  
Over 1,000 trained social prescribing link workers will be in place by April 2021, rising 
further by April 2024, with the aim that over 900,000 people are able to be referred to 
social prescribing schemes by then. This will mean many more patients who wish to take 
more responsibility for their health and well-being, while still receiving care, support and 
encouragement from the NHS, will be able to do so.  
Social prescribing relies on there being a good supply of safe and effective third sector 
provision, including information provision (local and national), online peer support and 
health coaching, talking therapies, self-management education programmes (generic and 
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conditions specific, face to face and online), ‘alternative’ health therapists and apps that 
are supported or endorsed by the NHS underpinned by the new Digital Assessment 
Criteria for Health and Care (DTAC). Many CCGs are already working in partnership with 
local authorities to co-commission community activities. However, voluntary community 
and social enterprise (VCSE) investment needs to be systematically supported across 
every local area.  
5.8 Our ambition 
The Review has avoided setting targets for the reduction of overprescribing. This is in part 
because of the difficulty of identifying the extent of overprescribing particularly with the 
current state of knowledge and research. However, the Review concluded that it was 
necessary to provide a benchmark, to give a sense of the scale of the problem and the 
benefits that would flow from implementing our strategy. The work on tackling 
overprescribing already underway – for example, the reductions achieved on antibiotics 
and the reductions in overprescribing in care homes through the Medicines Optimisation in 
Care Homes Programme – suggests that a reduction in the volume of prescription items in 
primary care of 10% is realistic. This would be equivalent to a reduction of around 110 
million items a year. One of the challenges for the implementation phase of the Review is 
to build up the analysis and evidence base sufficiently to allow this yardstick to be tested 
and refined, particularly as potential reductions are likely to vary in different care settings 
and for different medicines. 
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6. The system 
6.1 In this section: 
• Patient records, discharge letters and clinical indications 
• Treatment guidelines, clinical evidence and alternatives to medicine 
• Transfer of care, repeat prescriptions and regular reviews 
6.2 Patient records and discharge letters 
Although there is a great deal of work underway to improve the way patient records are 
kept and shared, we still have a national healthcare system where there is no single, 
complete comprehensive record of a patient’s medical history. The ability to view such an 
integrated record would allow practitioners to prescribe more safely and review medicines 
with more confidence. It would also make it easier for people receiving care to be more 
informed about, and involved in, decisions about that care, and better able to engage with 
care providers, including being able to add information to their own record. There are 
several ways to achieve this, all of which will require interoperability standards, coupled 
with adoption, to enable data to be shared and to ensure that full electronic records of 
individual patient’s medicines can be accessed and updated in real time by all those 
providing care. 
If we are to make shared decision-making a reality, there are symbolic and practical 
changes that need to be made to discharge letters to involve patients and carers. But they 
will remain a vital channel to communicate clinical information to GPs and others. The 
universal availability of a single, consolidated patient record which can be accessed and 
amended by all those providing health and social care may allow the clinical and patient-
facing elements of a discharge letter to be separated at some future point.  
For now, we can only set the desired outcome, which is that discharge letters and similar 
clinical communications are addressed to the patient, are written in clear, non-clinical 
language, are sent within the specified time and shared with all those providing care as 
appropriate, and which use mandated fields to ensure continuity of care on medicines. 
This work will also need to take account of the potential for discharge letters to help meet 
other parts of this strategy: for example, how best to use clinical and discharge letters to 
facilitate structured medication reviews and deprescribing by including a recommended 
minimum review period for hospital-initiated medicines.  
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R1.  NHSX should develop open standards and guidelines to ensure that records 
can be safely shared and accessed across care settings by patients and health and 
care professionals ultimately creating an interoperable consolidated patient 
medication record, and work with the Professional Record Standards Body to 
develop further mandatory standards for discharge letters. 
6.3 Clinical indications 
If the recording of clinical indications is to be improved, then prescribers need to have IT 
systems that make this as straightforward as possible. More training and guidance would 
also help ensure that prescribers appreciate how full and effective record-keeping helps 
their colleagues to manage treatment safely when care is shared or transferred. This 
should be underpinned by updating the Prescribing Competency Framework51 developed 
by the Royal Pharmaceutical Society, working alongside the other professional bodies, 
and the professional regulators, which sets out the standards expected of all prescribers. 
R2.  The Royal Pharmaceutical Society should revise the Prescribing Competency 
Framework to take account of the findings of this review and the increase in remote 
consultations and emphasise further that clinical indications must be routinely 
recorded at the point of prescribing; and NHSX and NHS Digital should work with 
stakeholders and system vendors to support the recording of indications within 
digital systems. 
6.4 Treatment guidelines 
These are vital tools for informing clinicians – and, increasingly, patients – about the ways 
in which a condition can be treated, and the benefits, risks and likely outcomes of different 
approaches. Guidance should be reviewed and extended so that it routinely sets out 
alternatives to medication, linked where available to clinical pathways and to improvement 
programmes such as GIRFT. Further, guidance should not only provide information on 
starting a medicine, but also how and when to stop a medicine, including review periods 
and indications for stopping.  
 
R3.  In developing and updating guidelines, NICE and professional bodies should 
include recommendations for reviewing and discontinuing medicines, where 
appropriate, and in the context of shared decision-making supported by decision 
aids.  
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6.5 Clinical evidence 
The limitations on data from clinical trials, particularly for older patients and those with 
multiple conditions, can be supplemented by monitoring of health outcomes across all 
patient groups once a medicine is in general use (known as, post-market surveillance). 
This information can then be made available to prescribers, particularly when considering 
when a medicine should be deprescribed. 
R4.  As part of its regulatory activity, MHRA should work with the pharmaceutical 
industry and clinicians to find a way for licensing and post marketing surveillance 
arrangements to generate information and insights that support deprescribing. 
6.6 Alternatives to medicines 
To take full advantage of social prescribing, the evidence and national and local options for 
non-medicine alternative treatments need to be fully integrated into prescribing systems as 
they develop. The evidence needs to be incorporated into national guidelines on 
conditions, and clinical practice templates should be adapted to ensure easy access to 
tools and resources to support decision-making by clinicians and patients with direct read-
across to menus of options across a range of conditions. 
R5.  NHSX and NHS Digital should work with GP IT system providers to develop 
integrated templates that support referrals for culturally competent, evidence-based 
alternatives to a medicine (including physiotherapy, talking therapies, local social 
prescribing options) which support Shared Decision Making and which can be 
adapted for local use. 
6.7 Transfer of care 
Although Medicines Reconciliations are usually performed by a pharmacist or pharmacy 
technician, other health and social care professionals may be well-placed to carry them 
out, given the right training and support. For example, a district nurse may see a patient to 
change a dressing and realise there is a discrepancy. The scope for extending Medicines 
Reconciliation will vary in different settings but there is a still a need for concerted action to 
extend the use of Medicines Reconciliation in Health and Justice settings and other non-
hospital sectors such as GP practices and care homes. Although there are new 
developments underway, such as the community pharmacy Discharge Medicines Service, 
current guidance on what constitutes Medicines Reconciliation still needs to be updated.  
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R6.  NHS England and NHS Improvement should support the expansion of 
medicines reconciliation at care transitions, including for a wider range of 
professionals, for example care home staff, through producing updated guidance 
and commissioning training within specific sectors.  
6.8 Repeat prescriptions 
When a course of medicine proves effective, it is natural for clinicians to continue to 
prescribe and patients to continue to take the medicine over an extended time. One way to 
improve the repeat prescribing system is to use Electronic Repeat Dispensing (eRD). This 
is more flexible for patients, who can gain confidence that the medicines they need will be 
there when they need them and will have less incentive to stockpile. It can also save a lot 
of time at GP surgeries: in one study, freeing up GPs by up to 45 minutes a day.11 This 
allows prescribers more time to concentrate on the prescriptions that require their input. 
COVID-19 has accelerated this process, and this should be encouraged and extended.  
There are also information, resources and training needs for reception team members and 
other non-clinical staff, so they are confident to support better repeat prescribing 
processes and deal with patient enquiries. Information and training will also help staff 
communicate other developments such as structured medication reviews and social 
prescribing to patients. The training would include cultural competency and safety as well 
as local procedures. 
Alongside this, Electronic Health Records (EHR) need to be analysed in each GP practice 
to help identify patients where patterns in their repeat prescriptions may make them 
suitable for a structured medication review or who have transferred from one care setting 
to another. EHRs should also be set up to provide structured data to support the 
evaluation of effectiveness and surveillance for unintended consequences. 
R7.  The Royal College of General Practitioners and the Royal Pharmaceutical 
Society should develop a national toolkit to help practices improve the consistency 
of repeat prescribing processes and support this with training resources for GP 
practice reception and administration teams.  
6.9 Regular reviews 
Expanding the number of clinical pharmacists in Primary Care Networks and widening the 
use of Structured Medication Reviews (SMRs) are key approaches in the LTP aimed at 
addressing overprescribing. 52 SMRs have not been defined too closely, to allow for 
flexibility in how they are provided in different settings and circumstances. For example, 
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there is currently no fixed length for a SMR, though they are expected to last at least 30 
minutes. It is important that SMRs are maintained in terms of their quality, including the 
time allocated for each one and the experience of patients taking part. 
SMRs need to be conducted in a way that maximises the scope for shared decision-
making. For example, we heard from patients about how they prepared for reviews of their 
treatment by thinking about what they wanted from the session, including noting down in 
advance any questions or areas of concern. The NHS England and NHS Improvement 
guidance states that this should be a standard suggestion in the information provided to 
patients and the communication inviting participants to attend a SMR. 
PCNs are required to identify and prioritise patients who would most benefit from a SMR. It 
is intended that over the duration of the LTP the number of patients who can be offered an 
SMR will expand. Clinical areas such as problematic prescriptions of dependence-forming 
medicines will require additional time and trust between the patient and professionals, and 
the timely availability of alternatives and support services. 
Those most in need of SMRs may be concentrated in deprived areas, and unless SMRs 
are adequately supported this may widen health inequalities. In addition, some patients, 
such as those with learning disabilities, or who face language or cultural barriers, may find 
it more difficult to engage in SMRs. Those providing SMRs may need to offer additional 
support for patients who may require an interpreter or wish to be accompanied by an 
advocate or carer, and ensure that information is provided in an accessible form and 
where possible in a range of languages.53 
 
R8.  NHS England and NHS Improvement should expand the use of SMRs in primary 
care networks to benefit those target groups most at risk of overprescribing, with 
resources to support practice teams and maintain standards. Appointments must 
be long enough to allow for shared decision-making – typically at least 30 minutes – 
and social prescribing link workers should be trained to help support patients after 
a SMR. 
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7. Culture 
7.1 In this section: 
• Awareness and behavioural change 
• Patient engagement and cultural competence 
• Human factors 
• Industry transparency 
7.2 Awareness and behavioural change 
Alongside changes to structures and systems, we need to help healthcare professionals 
and the public to work together to change the culture of prescribing. The immediate task is 
to identify the drivers for and barriers to behavioural change, and the culturally competent 
messages and other interventions that would help. Much of the additional insight will come 
through the research programme outlined in Section 8, but there is also a need to set a 
baseline and track awareness, understanding and behaviour change though an annual 
survey. 
This insight will help inform a national conversation about the limits to medicines and the 
efficacy of alternatives, including the role people can play in their own health and 
wellbeing. Prescribing is familiar to every clinician and every patient, and there are 
therefore many opportunities to use existing channels and messages to promote 
behaviour change, and for a National Clinical Director for Prescribing guided by 
stakeholders including the NHS Assembly to engage with the media and opinion-formers 
to explain and discuss a set of issues that are often of very great interest to their 
audiences.  
Rather than duplicate work already underway, the focus on professional engagement 
should be to work with and support existing channels and bodies, notably the Academy of 
Medical Royal Colleges. This would include support for the development of a national 
strategy for the implementation of the Rethinking Medicine approach, which could include 






R9.  NHS England and NHS Improvement guided by the NHS Assembly should lead 
changes in awareness, understanding and behaviour amongst healthcare 
professionals and the public, tracked by an annual survey of behaviour change on 
prescribing, and supported by work with the Academy of Medical Royal Colleges to 
develop a strategy that encourages the Rethinking Medicine initiative and supports 
its implementation, including encouraging multi-professional leadership.  
 
7.3 Patient engagement and cultural competence 
Medication reviews, shared decision-making, social prescribing and other ways to reduce 
overprescribing depend critically on people being confident to challenge and be more 
involved in decisions about their care. Developing a simple tool to give patients and their 
carers better information about the medicines they are taking, or being advised to take, is 
a clear priority, while also considering language, culture and other barriers to 
communication. 
Cultural competency and sensitivity is of particular importance for the successful uptake of 
social prescribing and shared decision-making across all communities and this includes 
ensuring that those providing services or activities through social prescriptions are also 
inclusive and show cultural sensitivity. This should include wide consultation with sources 
of advice and expertise, including the new NHS Race and Health Observatory, the Health 
and Wellbeing Alliance and other stakeholders.  
R10.  NHSX and NHS Digital should ensure the NHS website and the NHS App give 
people culturally competent information about their medication, initially covering 
the majority of medicines being prescribed in primary care and allowing them to 
feedback adverse reactions. 
 
7.4 Human factors 
Electronic health records increasingly use ‘flags’ (automatic prompts or ‘pop-ups’) and 
other digital tools to guide prescribers towards specific decisions regarding prescribing or 
treatment. These tools aim to ensure that each prescription is appropriate, is as safe as 
possible, and gives the best value to the NHS. An example would be where a medicine 
safety bulletin is turned into a flag in the prescribing software rather than relying on a 
prescriber reading the bulletin itself.  
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However, there is currently no assessment of the quality of these digital tools, no national 
standards relating to their design or technical implementation, and no large-scale 
monitoring or evaluation of their impact on clinical care. Development tends to take place 
in isolation, with a lack of openness, rather than through a community of developers, users 
and researchers sharing evidence on effectiveness. There is also a lack of underlying 
evidence and research, particularly on issues such as alert fatigue and human factors. The 
risks include: 
• fatal medication errors linked to poor design of Electronic Health Records, as 
highlighted by the Healthcare Safety Investigation Branch54 
• ‘alert fatigue’, where over-use reduces their effectiveness 
• ensuring that all prescribers receive an alert 
• poor design leading to missed information or misinterpretation 
• the lack of an audit trail to record whether a prescriber has seen or acted on a 
flag when prescribing for a particular patient 
R11.  NHSX and NHS Digital should commission research teams to review, develop 
and evaluate digital decision-support tools; and work with GP IT system providers 
to ensure that these products support safe and appropriate prescribing. They 
should also ensure that digital systems and records make structured medication 
reviews a simple task. 
7.5 Industry transparency 
Medicines optimisation depends on clinicians making unbiased decisions on the medicines 
they prescribe and patients having confidence that these decisions are not distorted by 
commercial influences. Transparency initiatives such as Disclosure UK, where 
pharmaceutical companies, NHS organisations and health care professionals openly list 
pharmaceutical industry sponsorship, are very welcome and should be encouraged further 
as the pharmaceutical industry reacts to new forms of clinical practice. The NHS too will 
need to ensure its policies on conflict of interest remain fit for purpose and are adequately 
implemented. 
R12.  The Association of the British Pharmaceutical Industry should ensure 





8.1 In this section: 
• Leadership 
• Research and evaluation 
• Workforce, training and development 
• Data analytics 
• Sustainability 
8.2 Leadership 
In normal times, we would have included indicative deadlines or milestones in our 
recommendations. The COVID-19 pandemic prevents this, but this work programme 
needs a sense of urgency as well as the commitment of partner organisations. This will 
need to take account of the changes that COVID-19 have brought about in the NHS and to 
how people think about their own health and wellness. The Short Life Working Group has 
offered to reconvene within a year of this report’s publication to review implementation. In 
the meantime, the early implementation phase will need to establish where existing targets 
and metrics may need to be updated and new ways of measuring success put in place.  
Our strategy for tackling overprescribing is deliberately designed to work with and through 
a range of other initiatives and work streams, and within the overall framework of the Long 
Term Plan. This is a strength: but it brings with it the risk of the Strategy losing focus or 
momentum. The Review has concluded that it is essential that a senior individual at 
National Clinical Director level takes the lead in implementing the strategy, including 
liaison with others whose work will contribute to its overall success.  
R13.  NHS England and NHS Improvement should develop a funded programme of 
work in partnership with relevant national organisations to implement this review 
over the next three years. Led by a new National Clinical Director for Prescribing, 
implementation should be co-ordinated with other workstreams, including the NHS 
Long Term Plan medicines optimisation and personalised care work, PHE’s 
Prescribed Medicines Review Report, and the UK National Action Plan on 
Antimicrobial Resistance. To support the National Clinical Director, and working 
with the Regional Medical Directors and Regional Chief Pharmacists, Integrated 
Good for you, good for us, good for everybody 
47 
Care Systems should appoint senior, experienced and authoritative pharmacy 
leadership.  
 
8.3 Research and evaluation 
We do not yet fully understand the causes of overprescribing, both at the individual and 
system level, or the consequences. Even varied and inconsistent use of terminology (as 
with the term polypharmacy) can hamper consistency in the interpretation of data and for 
commissioning future research. We also need new ways of measuring overprescribing 
which account for the appropriateness or otherwise of prescribing, and that can be 
implemented using routine clinical data.  
Although reductions in prescribing can be achieved, there is as yet no conclusive evidence 
for whether overprescribing interventions lead to improvements in clinical and patient 
outcomes. There is also limited robust evidence telling us how best to manage 
overprescribing, and this is reflected in a lack of relevant evidence-based clinical guidance. 
This does not in any way undermine concepts such as medicines optimisation or social 
prescribing. Instead, it reflects a need to better understand how we design and deliver 
interventions.  
Solutions for overprescribing need to be placed within a system-wide context to address 
the many different factors that lead to overprescribing. This includes understanding which 
patients are most affected, which stakeholders are involved, the impact of different clinical 
or cultural factors, and the nature of resource constraints. This will enable clinicians and 
policy makers to identify underlying causal factors, which can be used to support change 
in service design and delivery.  
All this points to the need for substantial co-ordinated research. This should inform: the 
adoption of a consensus definition of polypharmacy, and include analysis and 
segmentation of those who experience polypharmacy to support the targeting and 
evaluation of interventions; mapping health systems to understand the causes of 
overprescribing and prioritise solutions; understanding the consequences of 
overprescribing; and evaluation of the impact and outcomes of the interventions for 
overprescribing set out in this report. 
R14.  The Department of Health and Social Care and the National Institute for Health 
Research should establish substantial co-ordinated research to strengthen the 
evidence base for overprescribing, including setting research priorities and 
providing coordination across the research community.  
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We saw in section two that the available evidence on overprescribing suggests it is linked 
to deprivation and to ethnicity as well as to age. It is urgent that we explore these links 
further and so can understand how to reduce health inequalities in different areas and 
between different patient groups.  
R15.  NIHR should prioritise further research into the links between overprescribing, 
deprivation, ethnicity and inequalities and the impact this has on the health of the 
population. 
8.4 Workforce, education and training 
The principles of good prescribing and diagnosis are already to be found in the education 
and training provided to clinicians – and every day, clinicians apply them. Prescribers do 
not need to be trained to do something fundamentally new. Rather, the task is to update 
training and development to reflect the growing understanding of overprescribing – its 
causes, consequences and remedies.  
This should cover all healthcare professionals, from undergraduate level through to 
Continuing Professional Development, and include: 
• identification of patients who would benefit from a Structured Medication 
Review 
• how to conduct a Structured Medication Review and complete medicines 
optimisation 
• encouraging and facilitating shared decision-making, the importance of 
listening to patients, and cultural competency 
• deprescribing and identifying adverse drug events and instances where harm 
outweighs benefit 
 
R16.   The health professional regulators, drawing on the advice of professional 
leadership bodies and Health Education England, should ensure their professional 
standards and outcomes for initial education and training, and standards or 
processes influencing professional development, including revalidation, supports 
the implementation of this review.  
The NHS Long Term Plan is increasing the number of posts for pharmacists and 
pharmacy technicians in the NHS and our recommendations would extend this demand 
further. It is vital that the workforce is able to expand to fill these extra roles without any 
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dilution of quality. This means the healthcare system as a whole will need to expand 
provision of training and development, including upgrading existing skills.  
R17.  The Department of Health and Social Care should work with the General 
Pharmaceutical Council, and wider stakeholders to support the safe and rapid 
implementation of the pharmacist initial education and training reforms, including 
allowing for more extensive clinical placements. The General Pharmaceutical 
Council should develop a similar programme for pharmacy technicians.  
 
R18.  HEE should develop an educational framework that facilitates the current 
registered pharmacy professional workforce to have their enhanced and standard 
level of clinical skills recognised. This framework should include the opportunity to 
extend independent prescribing by pharmacists. It should also introduce a standard 
of practice and professional development for those in population health roles, such 
as medicines optimisation teams, and include data science skills. 
8.5 Data analytics 
  
Data on NHS prescriptions dispensed in primary care is collected via the system for 
reimbursing community pharmacists and dispensing doctors. In secondary care, Electronic 
Prescribing and Medicines Administration (ePMA) is being introduced by individual Trusts 
but does not have universal coverage. In other areas, such as where prescriptions are 
issued by private providers or in the criminal justice system, there is no single system. 
Furthermore, available data is not consistently shared with third-party researchers.  
In order to better understand prescribing data, it is important to analyse the data to provide 
effective insights into how medicines are prescribed. This can often be achieved by 
creating an environment where data is de-identified and can be safely and appropriately 
accessed in order to do so, such as in a Trusted Research Environment. An example of 
the intended approach would be the data analytics platform of OpenSAFELY. This will 
enable the benefits that come from having “many eyes” on the data, without compromising 
confidentiality or privacy, and will support the development of a diverse ‘ecosystem’ of 
analytic approaches and more research. Any move to increase appropriate and safe 
access to health data has to maintain public trust and confidence. The best way to do this 
is to be open about the aims, benefits and any risks, and engage with the public and 
patient groups from the start.  
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Unfortunately, data is often held in silos which can make it difficult to access for open 
analysis and analysis can be conducted behind closed doors. In addition, Information 
Governance (IG) – which is intended to facilitate the safe and appropriate use of data – 
can be seen as confusing by staff and so they may become more risk averse to sharing, 
even when it is appropriate to do so. IG has become an excuse to block the sharing of 
data, particularly where the data holders overstate the risks and underplay the benefits. By 
continuing to increase access to prescribing data and supporting staff to navigate IG and 
become confident to do so, NHSX can help foster the development of an effective, open 
‘ecosystem’ of data analytics.  
Similarly, services such as PrescQIPP and OpenPrescribing have shown the value of 
drawing on the experience and creativity of independent commercial and not-for-profit 
providers. This approach should be extended to include funding for nationally-accessible 
data audit and feedback tools. Toolkits (for example, for repeat prescribing) and learning 
sets (for example, for deprescribing) may also help to accelerate the uptake of new 
approaches, alongside formal training and CPD. The review also heard that there was a 
potential gap in provision of training in the skills needed to use data better to improve care; 
again, this could be addressed by bringing in new organisations. 
R19.  NHSX and NHS England and NHS Improvement should lead on improving 
appropriate access to data on patient treatment, engaging early on with patients and 
patient groups on risks and benefits; help empower staff to become confident 
navigating the IG landscape; foster a diverse data analytics community and further 




Waste medicines are a significant burden and need to be disposed of carefully, to avoid 
harm to patients and the public, and to minimise harm to the environment. The 
manufacture and distribution of medicines, and the use of some medicines, has a 
significant impact on greenhouse gases. It is estimated that medicines account for 25% of 
the NHS carbon footprint. The NHS commitment to become carbon net zero is a great step 
forward, and commitments on reducing use of specific medicines, such as inhalers and 
anaesthetics, with high carbon impacts risks are important, but it could go further in 
reducing unnecessary prescribing and reducing waste, and ensuring medicines 
procurement policies take into account manufacturers, suppliers and distributors 
commitment to sustainability. Equally, the government must make sure that it adds its 
weight to medicines sustainability as part of the NHS’s ambitious and world leading plan to 
tackle carbon emissions. 
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R20.  NHS England and NHS Improvement should assess and support system 
action to address the carbon impact of unnecessary prescribing and medicines 
waste. This should include using procurement leverage to influence medicines 
manufacturers, suppliers and distributors to ensure they are aligned to the NHS net 
zero carbon ambition. Alongside this, DHSC should continue to support NHS 
England and NHS Improvement’s important work on sustainable medicines use 
across government, ensuring there is sufficient senior leadership through the NHS 




Annex A: How the review operated 
A.1 Our approach 
 The formal remit for the Review was: 
 
• addressing inappropriate polypharmacy – where a patient is taking multiple 
medicines unnecessarily 
• creating a more efficient handover between primary and secondary care, for 
example ensuring General Practitioners (GPs) have the data they need and feel 
able to challenge and change prescribing initiated in hospitals 
• improving management of non-reviewed repeat prescriptions – including 
encouraging patients to ask questions about their treatment to ensure they don’t 
remain on repeat prescriptions which are no longer needed 
• the role of digital technologies in reducing overprescribing 
• the increased role for other forms of care, including social prescribing 
The Review ran an Opening Symposium to gather initial thinking, particularly on scope and 
priorities, from a wide range of stakeholders. This report was provided to the Short Life 
Working Group (SLWG) for consideration. 
 
Five subgroups of the SLWG were set up, each chaired by an expert member of the 
SLWG. Subgroup membership was determined by the subgroup chair and consisted of 
healthcare professionals across specialisms and included representation from primary and 
secondary care and from patients. Each subgroup was provided with a problem and brief 
and their members used their experience and networks to develop evidence-based 
recommendations to reduce overprescribing nationally. These were presented and 
discussed at SLWG meetings. The chairs worked together to ensure the final 
recommendations covered all key areas and recognised the overlap between key areas 
within their subgroups.  
 
Subgroups were provided with the following reports, commissioned and completed on 
behalf of the review, to aid them in developing recommendations:  
 
• the National Overprescribing Review Opening Symposium Report 
• the Patient Experience Based Co-Design Event report 
• patient focus groups and in-depth interviews 
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• the Economic Methods of Evaluation Policy Research Unit report: Evidence for the 
impact of interventions for, and medicines reconciliation in, problematic 
polypharmacy 
A.2 Short Life Working Group membership 
Name Job title Affiliation 
Chair: Dr Keith 
Ridge  




Professor of Healthcare 
Improvement Research  
University of Leicester 
Gareth Arthur Director of Strategy and Policy, 
Specialised Commissioning  






University of Manchester 




Richard Cattell Deputy Chief Pharmaceutical 
Officer 
NHS England and NHS 
Improvement 
Dr Paul Chrisp Director of the Centre for 
Guidelines 
National Institute for 
Health and Care 
Excellence 
Professor Alf Collins Clinical Director, Personalised 
Care Group 
NHS England and NHS 
Improvement 
Tim Donaldson Chief Pharmacist Northumberland Tyne 
and Wear NHS 
Foundation Trust 
Tom Gentry  Senior Lead - Health and Care 
Policy 
AgeUK 
Dr Ben Goldacre Director, EBM DataLab University of Oxford 
Richard Goodman Regional Chief Pharmacist 
(London) 




Chief Pharmaceutical Officer’s 
Clinical Fellow 2018/19 and 
Clinical Lead, National 
Overprescribing Review 




Chair Royal College of 
General Practitioners 
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Name Job title Affiliation 
Dr Yvonne Morrissey  Consultant Geriatrician British Geriatrics Society 
and the Royal College of 
Physicians  
Dr Shaba Nabi General Practitioner and 




Lelly Oboh Consultant Pharmacist – Care of 
Older People, Guy’s and St 




Dr Raliat Onatade Group Chief Pharmacist and 
Clinical Director for Medicines 
Optimisation 
Barts Health NHS Trust 
Dr Raj Patel Deputy Director of Primary Care NHS England and NHS 
Improvement 
Dr Rupert Payne Consultant Senior Lecturer in 
Primary Health Care 
University of Bristol 
Claire Potter  Head of Prescribing Policy and 
Legislation 
Department of Health 
and Social Care 
Heather Randle Professional Lead for Education 
(including Medicines 
Management) and Primary Care 
Royal College of Nursing 
Keith McDonald 
 





Elaine Trainor Senior Nurse, System 
Transformation 




National Clinical Director for 
Older People 
NHS England and NHS 
Improvement 
Ed Waller Director for Primary Care 
Strategy and NHS Contracts 
NHS England and NHS 
Improvement 
Dr Patricia Wilkie  President  National Association for 
Patient Participation 
Steve Williams Senior Clinical Pharmacist  Poole Bay and 
Bournemouth Primary 
Care Network   
Julie Wood Former Chief Executive (up to 
30 June 2020) 
NHS Clinical 
Commissioners 
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A.3 Sub-groups 
The subgroups were chaired by members of the SLWG: 
 
• Culture and practice of prescribing including social prescribing – Professor Alf 
Collins 
• The role of digital technologies – Dr Ben Goldacre 
• Transfer of care – Dr Raliat Onatade 
• Improving the management of repeat prescribing – Dr Raj Patel 
• Research and Evidence – Dr Rupert Payne 
 
Over 90 people were members of the subgroups, advising on the recommendations on 
behalf of healthcare and other professionals. This included: 
 
• clinicians 
• policy makers 
• patient representatives 
• ALB representatives 
• professional body representatives 
 
We would like to thank the chairs and participants of the subgroups for giving their time 
and for their expert advice.  
 
A.4 Summary of consultation and engagement 
The Review’s professional and patient engagement activity included: 
 
• the five subgroups: combining the expertise of a pool of 90 members, formed from 
experts, interested professionals and patient representatives 
• examples of good practice: over 70 submissions received and presented at the 
Opening Symposium 
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• the Opening Symposium: 150 delegates across medicine, nursing and pharmacy, 
alongside arm’s length bodies (ALBs), patients, patient representatives and 
charities 
• Patient Experience Based Co-Design Event: held in conjunction with Health Watch 
Leeds, HealthWatch Calderdale, the Yorkshire and Humber AHSN and Me and My 
Medicines 
• patient research: focus groups and in-depth interviews with targeted segments of 
the population including underserved groups, conducted by an independent 
research agency 
• patient and professional engagement to review the final recommendations from all 
subgroups 
 
Focus groups were held to explore the attitudes of patients with serious and long-term 
conditions towards medicines and prescribing, and the concepts of overprescribing, 
medicine reviews and social prescribing, to inform the National Overprescribing Review. 
The groups were configured as below: 
 
 
Group Date Place Demographic Split No. of participants 
G1 22/1/2020 London ABC1 6 
G2 22/1/2020 London C2DE 6 
G3 23/1/2020 Leeds ABC1 6 
G4 23/1/2020 Leeds C2DE 6 
G5 29/1/2020 Rochdale All female C2DE 6 
G6 29/1/2020 Rochdale All male C2DE 6 
G7 30/1/2020 Long Eaton ABC1 6 
G8 30/1/2020 Long Eaton C2DE 6 
 
 
In-depth interviews were undertaken to allow people who had shown an interest in 
participating in the groups but were unable to attend an external venue to take part.   
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Individual Gender Age Demographic 
D1 Male 43 D 
D2 Female 78 C1 
D3 Female 45 C2 
D4 Female 53 C2 
D5 Male 54 C1 
D6 Female 29 C2 
D7 Male 50 C1 
D8 Female 24 D 
D9 Male 66 B 
D10 Female 20 C1 
 
In addition to the original research, six further groups were held to ensure that the 
perspectives of Black, Asian and Minority Ethnic patients were fully included in the 
National Overprescribing Review. 
 
Group Date Gender 
G1 30/07/2020 1 female, 3 male, 
G2 31/07/2020 3 female, 2 male 
G3 03/08/2020 2 female, 2 male 
G4 04/08/2020 3 female, 1 male 
G5 05/08/2020 2 female, 1 male 
G6 06/08/2020 1 female, 3 male 
 
Participants self-selected the description of their ethnicity and the totals were:  
 
• Asian / Asian British (including mixed race) 9  
• Black / Black British (including mixed race) 13  
• Other (non-white) 2 
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A Patient Experience Based Co-Design Event was run in Leeds in conjunction with Health 
Watch Leeds, Healthwatch Calderdale, the Yorkshire and Humber AHSN and Me and My 
Medicines. There was a mixed demographic of 25 (13 men, 12 women) patients and 
carers who attended the event. The range of conditions included diabetes, mental ill-
health, HIV, osteoarthritis, atrial fibrillation, chronic pain and Raynaud’s disease. The 
number of medications taken daily was between five and fifteen. 
 
Analysis and case studies were considered for groups where data or focus groups were 
not undertaken, including the Stopping over medication of people with a learning disability, 
autism or both (STOMP) and STOMP-STAMP (Supporting Treatment and Appropriate 
Medication in Paediatrics) programmes. 
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Annex B: Equality and health inequalities 
 
The NHS has a moral and legal duty to tackle health inequalities, particularly where they 
are caused by discrimination by age, gender, ethnicity or other protected characteristics.  
 
NHS England and NHS Improvement: Equality and Health Inequalities Impact 
Assessment (EHIA) template: 
 
A completed copy of this form must be provided to the decision-makers in relation 
to your proposal. The decision-makers must consider the results of this assessment 
when they make their decision about your proposal.  
 
1. Name of the proposal (policy, proposition, programme, proposal or initiative): 
National Overprescribing Review 
 
2. Brief summary of the proposal in a few sentences 
 
The Secretary of State for Health and Social Care commissioned a review to be led by 
Dr Keith Ridge, the Chief Pharmaceutical Officer for England, to evaluate the extent of 
overprescribing in the NHS and recommend what might be done to reduce this problem, 
particularly in primary care. 
 
The National Overprescribing Review was set up to develop a strategy to reduce 
overprescribing, where people are given medicines they don’t need or want, or which 




3. Main potential positive or adverse impact of the proposal for protected 
characteristic groups summarised 
 
Please briefly summarise the main potential impact (positive or negative) on people with 
the nine protected characteristics (as listed below). Please state N/A if your proposal will 
not impact adversely or positively on the protected characteristic groups listed 




Summary explanation of 
the main potential 
positive or adverse 
impact of your proposal  
Main recommendation from 
your proposal to reduce any 
key identified adverse impact 
or to increase the identified 
positive impact 
Age: older people; 
middle years; early 
years; children and 
young people. 
The main positive impact of 
the proposal is that all 
patients, particularly groups 
with a higher prevalence of 
polypharmacy are able to 
benefit from the 
implementation of the 
All recommendations are 
proposed to reduce 
overprescribing, where people 
are given medicines they don’t 
need or want, or which may do 
them harm.  
 
Disability: physical, 





Summary explanation of 
the main potential 
positive or adverse 
impact of your proposal  
Main recommendation from 
your proposal to reduce any 
key identified adverse impact 




recommendations to make 
sure that medicines they 
don’t need or want, or 
which may do them harm 
are reduced. 
Overprescribing can have a 
physical and mental impact 
of on patients, it can lead to 
more hospital visits and 
preventable admissions, 
even premature deaths. 
Reducing overprescribing 
aims to achieve better 
patient outcomes for all. 
 
The recommendations to 
reduce overprescribing will 
also benefit all groups as 
the cost of wasted 
medicines diverts money 
from paying for the 
medication people really 
need and can cause harm 
to the environment. 
 
The recommendations also 
support implementation and 
roll out of existing initiatives 
such as; social prescribing, 
personalised care, including 




Personalised care has been 
shown to help reduce 
health inequalities, giving 
The recommendations have 
been developed taking account 
of: 
• Data on protected 
characteristics and other 
groups that face health 
inequalities where this was 
available (age, sex, ethnicity 
and deprivation). 
• Feedback from patients, 
particularly those that the 
data demonstrates may be 
more likely to have 
problematic polypharmacy 
e.g. older people, people 
with disabilities and those 
from communities with high 
levels of deprivation. 
• Feedback and advise from a 
range of other sources as 




people who identify 
as Transgender 
Marriage & Civil 
Partnership: people 




before and after 
childbirth and who are 
breastfeeding. 
Race and ethnicity2 
Religion and belief: 
people with different 
religions/faiths or 
beliefs, or none. 
Sex: men; women 
Sexual orientation: 




2 Addressing racial inequalities is about identifying any ethnic group that experiences inequalities. Race and ethnicity 
includes people from any ethnic group incl. BME communities, non-English speakers, Gypsies, Roma and Travelers, 
migrants etc who experience inequalities so includes addressing the needs of BME communities but is not limited to 
addressing their needs, it is equally important to recognise the needs of White groups that experience inequalities. The 
Equality Act 2010 also prohibits discrimination on the basis of nationality and ethnic or national origins, issues related to 
national origin and nationality. 
 




Summary explanation of 
the main potential 
positive or adverse 
impact of your proposal  
Main recommendation from 
your proposal to reduce any 
key identified adverse impact 
or to increase the identified 
positive impact 
people choice and control 
over the way their care is 
planned and delivered 
based ‘what matters’ to 
them and their individual 
strengths, needs and 
preferences. It tailors health 
information to people’s level 
of health literacy and 
increases peoples’ capacity 
to use health information 
effectively and to identify 





4.  Main potential positive or adverse impact for people who experience health 
inequalities summarised 
 
Please briefly summarise the main potential impact (positive or negative) on people at 
particular risk of health inequalities (as listed below). Please state N/A if your proposal 
will not impact on patients who experience health inequalities.  
 
Groups who face 
health inequalities3  
Summary explanation of 
the main potential 
positive or adverse 
impact of your proposal 
Main recommendation from 
your proposal to reduce any 
key identified adverse impact 
or to increase the identified 
positive impact 
Looked after children 
and young people 
As above for section 3. 
 
As above for section 3. 




People on the street; 
staying temporarily with 
friends /family; in 
hostels or B&Bs. 
People involved in 
the criminal justice 
system: offenders in 
 
 
3 Please note many groups who share protected characteristics have also been identified as facing health inequalities 
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Groups who face 
health inequalities3  
Summary explanation of 
the main potential 
positive or adverse 
impact of your proposal 
Main recommendation from 
your proposal to reduce any 
key identified adverse impact 










People or families on 
a low income  
People with poor 
literacy or health 
Literacy: (e.g. poor 
understanding of health 
services poor language 
skills). 
People living in 
deprived areas 
People living in 
remote, rural and 
island locations 
Refugees, asylum 









5. Engagement and consultation 
 
a. Have any key engagement or consultative activities been undertaken that considered 
how to address equalities issues or reduce health inequalities? Please place an x in the 
appropriate box below.  
 
Yes  X No Do Not Know 
 
b. If yes, please briefly list up the top 3 most important engagement or consultation 
activities undertaken, the main findings and when the engagement and consultative 
activities were undertaken.  
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Name of engagement and 
consultative activities 
undertaken 
Summary note of the engagement or 
consultative activity undertaken 
Month/Year 
1 Focus groups and depth 
interviews with patients 
 
In total, fourteen patient/public focus 
groups and ten in depth interviews to 
cover targeted segments of the 
population, including hard to reach 
groups.  
The eight initial focus groups were held 
with patients who met one or more of 
the following criteria - had serious, 
long-term conditions; were taking 
multiple (5+) medications; had poor 
experiences with long-term medication.  
The ten in-depth interviews were with 
people who expressed an interest in 
participating in the groups but were not 
able to take part, for health reasons. 
Six further focus groups focused on 
health inequalities and BAME 
communities with regard to access to 
healthcare and prescribing. Participants 
in these groups were all from BAME 
communities who had multiple or long-
term conditions or who had used 
healthcare services within the previous 
12 months, and also resident in an area 
of high deprivation (using the highest 





















2020                                                    
 
    
2 Co-designed event with 
patients 
 
Patient Experience Based Co-Design 
event in conjunction with Health Watch 
Leeds, HealthWatch Calderdale, the 
Yorkshire and Humber AHSN and Me 
and My Medicines.  
 
There was a mixed demographic of 25 
(13 men, 12 women) patients and 
carers who attended the workshop. The 
range of conditions included diabetes, 
mental ill-health, HIV, osteoarthritis, 
atrial fibrillation, chronic pain and 
Raynaud’s disease. The number of 
medications taken daily was between 




    
3 Patient and professional 
engagement sessions 
Discussions of the draft 




Name of engagement and 
consultative activities 
undertaken 
Summary note of the engagement or 
consultative activity undertaken 
Month/Year 
 SLWG subgroups with healthcare 
professionals and with patient group 
representatives and patients to sense-
check the recommendations with 




6. What key sources of evidence have informed your impact assessment and are 
there key gaps in the evidence? 
 
Evidence Type Key sources of available 
evidence  
 Key gaps in evidence 
Published evidence • The Review bibliography 
contains a full list of published 
evidence. 
• The Review aligns with and 
builds on several other plans 
and initiatives that affect the 
provision of healthcare in 
England. These include the 
NHS Long Term Plan, Public 
Health England’s Prescribed 
Medicines Review Report, 
NHS England and NHS 
Improvement’s Medicines 
Safety Improvement 
Programme, and the current 
UK National Action Plan on 
Antimicrobial Resistance. 
See section 9 for Review 
recommendations to 
address research gaps. 
Consultation and 
involvement findings  
• The Review ran or 
commissioned: 
• An Opening Symposium with 
around 150 delegates from the 
medicine, nursing and 
pharmacy professions, from 
academia and from patient 
groups and charities;  
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Evidence Type Key sources of available 
evidence  
 Key gaps in evidence 
• A Patient Experience Based 
Co-design event with patients, 
in partnership with 
HealthWatch, the campaigning 
group Me and My Medicines, 
and the Yorkshire and Humber 
Academic Health Science 
Network;  
• Subgroup engagement with 
over 90 members, formed 
from experts, interested 
professionals and patient 
representatives; 
• 14 focus groups and 10 in-
depth interviews with patients 
and the public from an 
independent research agency.  
Research • Research commissioned from 
EEPRU (The Policy Research 
Unit in Economic Methods of 
Evaluation in Health and 
Social Care Interventions, a 
collaboration between the 
Universities of Sheffield and 
York and the National Institute 
for Health Research).1 
 
Participant or expert 
knowledge  
For example, 
expertise within the 
team or expertise 
drawn on external to 
your team 
• The Review was guided by a 
Short Life Working Group 
(SLWG). This brought 
together senior stakeholders 
from across the healthcare 
system, together with patient 
and third sector 
representation. The 
membership of the SLWG is 




Evidence Type Key sources of available 
evidence  
 Key gaps in evidence 
• Five subgroups, each one 
chaired by an expert member 
of the SLWG, developed the 
detailed recommendations. 
The subgroups drew on the 
expertise of ninety healthcare 
professionals and patient 
representatives. 
• A review team from NHS 
England and NHS 
Improvement provided support 
including a: Regional Chief 
Pharmacist, clinical, policy, 
communications and analytical 
leads. 
• Policy feedback was obtained 
through wider consultation 
with other NHSEI policy leads 
on draft recommendations. 
Data As described in the review 
technical annex (Annex E), data 
was utilised from multiple sources 
to understand: 
• Trends of prescribing over 
time in primary care. 
• Scale of polypharmacy 
including by age, sex, ethnicity 
and level of deprivation. 
• Links to prescribed medicines 
that may cause dependence 
and withdrawal. 
• Impact of other initiatives to 
tackle overprescribing e.g. 
antimicrobial resistance. 
Data for prescribing 
activity was not available 
for all protected 
characteristics and there 
are limitations of the data 
available on ethnicity as 
described in the review 
technical annex (Annex 
E).   
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7. Is your assessment that your proposal will support compliance with the Public 








    
The proposal will 
support? 
X X X 
    
The proposal may 
support? 
   
    
Uncertain whether 
the proposal will 
support? 
   
 
8.  Is your assessment that your proposal will support reducing health inequalities 
faced by patients? Please add an x to the relevant box below. 
 
 Reducing inequalities in 
access to health care 
Reducing inequalities in 
health outcomes 
   
The proposal will 
support? 
X X 
   
The proposal may 
support? 
  
   
Uncertain if the 




9.  Outstanding key issues/questions that may require further consultation, 





Key issue or question to be answered Type of consultation, research or 
other evidence that would address 
the issue and/or answer the 
question 
1 The Review recommends that the evidence 
base for overprescribing requires 
strengthening, including setting research 
priorities and providing coordination across 
the research community. Its recommends 
that a programme would include the 
adoption of a consensus definition of 
polypharmacy, analysis and segmentation of 
those who experience polypharmacy to 
support the targeting and evaluation of 
interventions, mapping health systems to 
understand the causes of overprescribing 
and prioritise solutions, understanding the 
consequences of overprescribing, and 
evaluation of the impact and outcomes of the 
interventions for overprescribing set out in 
this report. 
 
The review recommends that that 
Department of Health and Social Care 
should establish a funded research 
programme working with the Clinical 
Director for Optimised Prescribing. 
2 Further research needs to be undertaken 
into the links between overprescribing, 
deprivation, ethnicity and inequalities and 
the impact this has on the health of the 
population. 
 
The review recommends that NIHR 
should undertake this further research. 
 
This may also require access to more 
robust data on some of the protected 
characteristics e.g. ethnicity. As 
acknowledged in the report there are 
limitations of this data. The Unified 
Information Standard for Protected 
Characteristics (UISPC) is currently 
being developed which would aim to 
help monitor the impact of 
interventions on equality and health 
inequalities.  
  
3 The review implementation plan will need to 
ensure that there is adequate involvement of 
patients and other stakeholders in the design 
and rollout or any new interventions and that 
a robust evaluation process is integrated 
from the outset. 
 
Stakeholder engagement – a 
stakeholder engagement plan would 
be developed to support 
implementation of the 
recommendations to ensure that all 
patients impacted are able to 
contribute effectively. 
 
Further equality and health inequalities 
impact assessment would be required 
for implementation policy and plans. 
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10. Summary assessment of this EHIA findings 
 
The EHIA summarises the equality and health inequalities findings from the review used 
to develop recommendations which aim to reduce overprescribing. 
 
Everyone has a minimum of five characteristics given protection under the Equality Act 
2010, and we are conscious that our strategy to reduce overprescribing needs to take 
full account of the needs of groups with different protected characteristic. For example, 
good prescribing, social prescribing and structured medication reviews all depend on 
prescribers and patients having the best possible relationship with open communication, 
and we identify ways in which fostering the right culture in healthcare will help ensure 
that no protected characteristic group is disadvantaged. This includes, but is not 
restricted to, the discussion and recommendations on cultural competency. Although 
these are primarily focused on race and ethnicity, and to some extent on religion and 
belief, the approach we have recommended should also address the risk of exclusion or 
discrimination that might relate to sex, sexual orientation, gender reassignment and 
transgender groups, and pregnancy and maternity, particularly as there are some 
medicines or treatments that are particularly relevant to these groups. 
 
The Review recommendations apply to all patients, although particularly to those groups 
with a higher prevalence of polypharmacy. Successful implementation of the 
recommendations will mean that all patients are able to benefit from them, to make sure 
that medicines they don’t need or want, or which may do them harm are reduced to 
achieve more favourable outcomes. Reducing medicines waste also has a positive 
impact on ensuring that money is not diverted from medicines that people need and has 
environmental benefits which impact the whole population. 
 
Further EHIA will be required on development of an implementation plan to ensure that 
suitable engagement is undertaken nationally and locally, where appropriate to deliver 




11. Contact details re this EHIA 
 
Team/Unit name: Medicines Policy Unit 
Division name: Policy & Strategy 
Directorate name:  Specialised Commissioning 
Date EHIA agreed:  






Annex C: Case studies 
Title Organisation(s)
/area 
Case study links 
Me and My Medicines 
campaign 
Leeds, 




Science Network  
https://meandmymedicines.org.uk/  
Our Healthier Fleetwood 
healthy living and social 























and Deprescribing Review 
to address problematic 
polypharmacy  





High dose opiate 
reduction in Great 
Yarmouth and Waveney  
Great Yarmouth 





























Case study links 
Medicines Optimisation in 
Care Homes 



















The introduction of a 













Service in Primary Care  
Brighton and 
Hove CCG - part 
of the Central 






































Annex D: Key papers  
• Age UK report: More harm than good 
• The Canadian Deprescribing Network (CaDeN): Deprescribing Guidelines 
• Choosing Wisely UK initiative: Choosing Wisely UK 
• EEPRU report: Evidence for the impact of interventions for, and medicines 
reconciliation in, problematic polypharmacy: A rapid review of systematic reviews and 
scoping searches  
• EEPRU report: Prevalence and economic burden or medications errors in the NHS in 
England 
• The King’s Fund report: Polypharmacy and Medicines Optimisation  
• London Regional Medicines Optimisation Committee (RMOC) and SPS: 
Polypharmacy Working Group Report  
• National Institute for Health and Care Excellence (NICE) Guidance: Medicine 
Optimisation: the safe and effective use of medicines to enable the best possible 
outcomes 
• National Institute for Health and Care Excellence (NICE) Guidance: Multimorbidity: 
clinical assessment and management 
• Public Health England: Prescribed Medicines Review Report  
• The Quality Use of Medicines to Optimise Ageing in Australian Adults: 
Recommendations for a national strategic action plan to reduce inappropriate 
polypharmacy  
• Realistic Medicine Scotland 
• Rethinking Medicine 
• Royal Pharmaceutical Society: Polypharmacy – Getting our medicines right  
• The SIMPATHY project (Stimulate Innovation in the Management of Polypharmacy 
and Adherence in The Elderly). Results at: http://simpathy.eu/ 
• World Health Organisation global campaign: Medication Without Harm 
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Annex E: Technical information 
Some tables and data have already appeared in the main text 
 
Before we can fully understand the consequences of polypharmacy for overprescribing, we 
need more research and evidence. Current methods for measuring polypharmacy (such as 
counting medicines) are limited and may either fail to identify those patients most likely to 
benefit from optimisation of care, or are limited to narrow aspects of therapeutic 
management. Varied and inconsistent use of terms such as overprescribing, 
polypharmacy and inappropriate prescribing also make it difficult to quantify the issue. 
Problematic polypharmacy is a complex problem and each patient experiences it in a 
different way. There is a lack of understanding of the causes of overprescribing and 
problematic polypharmacy at both individual and system levels. This makes it more 
challenging to know which patients to target and why, and which aspects of prescribing to 
focus on. It is also unclear which outcomes should be the goal of service evaluations and 
interventions. 
E.1 The scale of polypharmacy 
In the primary care system in England between October and December 2019, 
approximately 27 million people were taking one medicine regularly, 8.4 million were 
taking five or more medicines and 3.8 million were taking eight or more unique medicines. 
Some people were supplied with more than forty medicines. 
Table 1: Spread of medications by number and rate per population.  
Number of patients (millions) Rate per 1,000 
population 
At least one medicine 27.0 480 
One medicine only 8.1 143 
Five or more 8.4 149 
Eight or more 3.8 68 
10 or more 2.2 38 
 
The average number of medicines dispensed to patients has been consistent over the last 
five years. For all patients, the mean number of medicines dispensed has consistently 
been around 3.9 and the median has been five. For patients on eight or more medicines, 
the mean has consistently been 10.9 and the median has been 12. 
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This suggests that polypharmacy – and by extension, problematic polypharmacy – is 
relatively stable for the average patient. However, it is clear that polypharmacy increases 
with age (Figure 2), most notably from the age of 40. By the age of 80, more than a third of 
all people are on eight or more medicines. As the population in England ages, with more 
people living longer, polypharmacy is forecast to increase as well. Unless action is taken, 

















Figure 2: Distribution of number of unique medicines by age (rate per 1,000 population) 
 
E.2 Polypharmacy and deprivation 
As Figure 3 shows, the number of people taking one or more medicine does not vary 
significantly between the areas of highest and lowest social and economic deprivation. In 
other words, those living in a relatively poorer area are not that much more likely to be 
taking medicine than the average. But those living in the most deprived areas are much 
more likely to be taking eight or more medicines (shown by the red line), and this 
difference is not down to the age or sex of the local population. Clearly, polypharmacy 
increases with relative deprivation, and the rate of those on eight or more medicines is 2.8 
times greater in the most deprived areas compared to the least deprived. What we cannot 
say from the data is the proportion of polypharmacy that is problematic: it could be that 
some or all of the difference is down to a higher rate of illness in more deprived areas. But 
it certainly increases the risk of overprescribing: for example, almost two in three people 
who are taking eight or more medicines are on at least one drug that may cause 
dependency.  
 




Figure 3: Prescribing rate and rate of patients on eight or more medicines by IMD decile, 
standardised by age and gender. 
 
E.3 Polypharmacy and ethnicity 
The work on polypharmacy and ethnicity is still very preliminary, but we have enough data 
and insight to suggest there are issues to be explored further. For example, we can see 
that from a sample in June 2019 of patients taking at least one medicine, that the 
proportion of patients on eight or more medicines varies by ethnicity, even allowing for 
differences in age.  The group with the highest proportion of those on 8 or more medicines 
(13.9%), are those who reported themselves as of Asian/Asian British ethnicity. The 
sample is broadly representative of ethnicity in the population at large but we don’t know 
the extent of any sampling bias in CPRD that might mean that for example the Asian group 
in the sample need more medicines than Asians in the country as a whole. The differences 
between some ethnic groups are not statistically significant, as shown by the confidence 
intervals, due to relatively low numbers of patients in these groups. Again, we cannot say 
from this data what proportion of polypharmacy amongst Black, Asian and Minority Ethnic 






Figure 4 – Age-standardised proportion of patients on eight or more medicines, by 
ethnicity 
 
E.5 Description of data sources and method for prevalence 
of polypharmacy  
 
The data comes from NHS Business Services Authority (BSA) Prescription Services and is 
derived from products prescribed on prescriptions and dispensed in the community. The 
database is taken to be a complete record of all prescriptions submitted for reimbursement 
by NHS BSA, excluding items identified as not dispensed, disallowed or returned. 
 
The number of medicines per person is specified by: 
 
• unique chemical substance for the prescription item. For example, Simvastatin and 
Atorvastatin are two separate chemical substances. The chemical substance is taken 
from the structure of the 2016 British National Formulary (BNF)  
• dispensed in any month of the three-month period 
• appliances are excluded, for example oxygen masks, dressings, or catheters  
For example, a person on eight medicines is defined as having had eight unique chemical 
substances dispensed to them at some point between October and December 2019, 
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though they may also have had appliances dispensed and several different presentations 
of the same medicine.  
 
The data relies on a successful match of prescription items dispensed to individual 
patients. The matching is done by NHS BSA using NHS Personal Demographic Service. 
Not all items can be successfully matched. The dataset used is based on successful 
matches that covers 95.0% of all prescription items. The patients included in the dataset 
cover 98.8% of all identified patients and 99.7% of all items linked to identified patients. 
The number of medicines per patient is therefore highly accurate but 1.2% of patients are 
missing from the dataset. 
 
Rates are expressed per 1,000 population. Population figures are taken from ONS mid-
year estimates (2019) except for analysis by deprivation where population figures for 2017 
are used as the latest available population data.  
 
The data for the analysis by ethnicity comes from the Clinical Practice Research Database 
(CPRD). It is based on the GOLD sample. The analysis is based on prescriptions made in 
June 2019 for medicines from BNF chapters 1 to 10 excluding chapter 5. Ethnicity 
information is available for half of patients in the sample. The total number of patients 
included in the analysis is 549,676. Confidence intervals have been applied to account for 
the smaller numbers of patients in certain ethnicity groupings.  
 
The GOLD sample is representative of the UK population in terms of age, gender and 
ethnicity56. However, we don’t know the extent of any sampling bias which might bias the 
prescribing pattern by ethnicity. For example, the sample suggests that those reporting 
themselves as of Asian/Asian British ethnicity have the highest proportion of patients on 
eight or more medicines, but this might be because these patients are sicker than the 
Asian group in the population at large. Preliminary analysis, using a multi-level Poisson 
model, suggests that these differences are not due to clustering of patients by GP practice. 
 
The table below shows the number of patients prescribed a medicine in June 2019, by 
ethnicity group: 
 
      
 Number of patients Proportion of patients 
White 515,659 47.2% 
Mixed 3,602 0.3% 
Asian/Asian British 16,992 1.6% 
Black/Black British 6,993 0.6% 
Chinese/Other 6,430 0.6% 
Missing 543,395 49.7% 
Total 1,093,071 100% 
 
The ethnicity groups are comprised as follows as per 2001 ONS census categories57: 
White 
 
• Welsh/English/Scottish/Northern Irish/British 
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• Irish 
• Gypsy or Irish Traveller 
• Any other White background 
 





• Any other Asian background 
 
Other ethnic group 
 
• Chinese 




• White and Black Caribbean 
• White and Black African 
• White and Asian 
• Any other mixed background 
 
Black or Black British 
 
• Black - Caribbean 
• Black - African 
• Any other Black background 
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